Cli nical St u d y Pr ot oc ol: X P O R T -C o V -[ADDRESS_209254] u d y t o E v al u ate t he Acti vit y a n d S afet y of L o w D ose 
Or al Seli ne x or ( K P T -3 3 0) i n P atie nts wit h Se vere CO VI D - 1 9 I nfecti o n  
(X P O R T- C o V- 1 0 0 1)  
St u d y N u m ber:  X P O R T -C o V -[ADDRESS_209255] u d y P h ase:  P hase [ADDRESS_209256]:  Sel i ne x or (X P O VI O ®, K P T -3 3 0) 
I n dic ati o n:  Se vere C O VI D -[ADDRESS_209257] a C T N u m ber:  
I N D N u m ber  2 0 2 0 -0 0 1 4 1 1 -2 5  
 
S p o ns or:  Kar y o p har m T hera pe utics I nc.  
8 5 Wells A ve n ue  
Ne wt o n, M A 0 2 4 5 9 U S A  
Tel. + ( 6 1 7) 6 5 8 -0 6 0 0  
Pr ot oc ol D ate a n d 
Versi o n:  2 7 Marc h 2 0 2 0, Versi o n 1. 0 ( Ori gi nal)  
0 5 A pril 2 0 2 0, Versi o n 2. 0 ( A me n d me nt 1)  
0 7 A pril 2 0 2 0, Versi o n 3. 0 ( A me n d me nt 2 - c o u ntr y s pecific U S)  
0 9 A pril 2 0 2 0, Versi o n 4. 0  ( A me n d me nt 3 - c o u ntr y s pecific U S)  
1 1 A pril 2 0 2 0, Versi o n 4. 0 ( A me n d me nt 4 - Gl o bal)  
1 5 A pril 2 0 2 0, Versi o n 4. 0 U K (c o u ntr y s pecific U nite d Ki n g d o m)  
1 8 A pril 2 0 2 0, Versi o n 4. 0 D E (c o u ntr y s pecific Ger ma n y)  
1 8 A pril 2 0 2 0, Versi o n 4. 0 I L (c o u ntr y s pecific Israel)  
0 2 Ma y 2 0 2 0, Versi o n 5. 0 (c o u ntr y s pecific U S)  
0 4 Ma y 2 0 2 0, Versi o n 1. 1 (c o u ntr y s pecific Ital y)  
0 8 Ma y 2 0 2 0, Versi o n 6. 0  (c o u ntr y s pecific U S)  
C O N D U C T  
I n acc or da nce wit h t he et hical pri nci ples t hat ori gi nate fr o m t he Declarati o n of Helsi n ki a n d t hat are 
c o nsiste nt wit h I nter nati o nal C o u ncil f or Har m o nisati o n (I C H) g ui deli nes o n G o o d Cli nical Practice 
( G C P) a n d re g ulat or y re q uire me nts as a p plica ble.  
C O N F I D E N TI A L I N F O R M A TI O N  
T his d oc u me nt is t he s ole pr o pert y of Kar y o p har m T hera pe utics I nc. ( Kar y o p har m). T his d oc u me nt a n d 
all i nf or mati o n c o ntai ne d herei n has t o be c o nsi dere d a n d treate d as strictl y c o nfi de ntial. T his d oc u me nt 
will be use d o nl y f or t he discl os ure herei n pr o vi de d. N o discl os ure or p u blicati o n will be ma de wit h o ut 
t he pri or writte n c o nse nt of Kar y o p har m.  
  C CI 
Cli nical St u d y Pr ot oc ol: X P O R T -C o V -1 0 0 1  Seli ne x or  
Versi o n 6. 0   0 8 Ma y 2 0 2 0  
C o nfi de ntial   Pa ge 2 of 7 4  P R O T O C O L A P P R O V A L SI G N A T U R E P A G E  
S P O N S O R: K A R Y O P H A R M T H E R A P E U TI C S I N C.  
I ha ve rea d a n d u n dersta n d t he c o nte nts of t his cli nical pr ot oc ol f or St u d y X P O R T -C o V - [ADDRESS_209258] u d y. 
A p pr o ve d B y:  
 
 
 M D  
 
K ar y o p h ar m T her a pe utics I nc.   
 
 
D ate  
 
 
 
 P h D  
 
K ar y o p h ar m T her a pe utics I nc.    
 
D ate  
 
 
  P P D 
P P D 
P P D 
P P D 
Clinical Study Protocol: XPORT -CoV -1001 Selinexor  
Version 6.0  08 May 2020 
Confidential   Page 3 of 74 INVESTIGATOR’S AGREEMENT  
 
I have read and understand the contents of this clinical protocol for Study XPORT -CoV-[ADDRESS_209259] the Study in accordance with 
current Good Clinical Practice, ICH E6, and applicable FDA regulatory requirements. 
 
 
________________________________________________________________________ 
Printed Name [CONTACT_7919]  
 
________________________________________________________________________ 
Signature [CONTACT_7919] 
 ________________________________________________________________________ 
Institution  
 
__________________________________________ 
Date  
 
  
Clinical Study Protocol: XPORT -CoV -1001 Selinexor  
Version 6.0  08 May 2020 
Confidential   Page 4 of 74 TABLE OF  CONTENTS  
PROTOCOL APPROVAL SIGNATURE [CONTACT_1783]  ...........................................................................2  
SPONSOR: KARYOPHARM THERAPEUTICS INC.  .................................................................2  
INVESTIGATOR’S AGREE MENT  ...............................................................................................[ADDRESS_209260] OF ABBREVIATIONS ..........................................................................................................9  
SYNOPSIS  13 
SCHEDULE OF ASSESSMENTS  ................................................................................................22  
1. INTRODUCTION  ......................................................................................................25  
1.1. Study Rationale ...........................................................................................................25  
1.2. Background on COVID-19 .........................................................................................25  
1.2.1.  Viral Shedding and Transmission ...............................................................................26  
1.2.2.  Cytokine Levels and Outcomes ..................................................................................26  
1.3. Selinexor .....................................................................................................................26  
1.4. Benefit/Risk Assessment  ............................................................................................30  
2. OBJECTIVES AND ENDPOINTS  ............................................................................31  
3. STUDY DESIGN  .......................................................................................................34  
3.1. Overall Design  ............................................................................................................34  
3.2. Scientific Rationale for Study Design  ........................................................................35  
3.3. Justification for Dose  ..................................................................................................35  
3.4. End of Study Definition ..............................................................................................35  
4. STUDY POPULATION  .............................................................................................36  
4.1. Inclusion Criteria  ........................................................................................................36  
4.2. Exclu sion Criteria  .......................................................................................................36  
4.3. Screen Failures  ............................................................................................................37  
4.4. Randomization/Stratification  ......................................................................................37  
5. STUDY TREATMENT  ..............................................................................................39  
5.1. Study Treatment Administered  ...................................................................................39  
5.2. Dosing and Administration of Selinexor/Placebo ......................................................39  
5.2.1.  Labeling ......................................................................................................................39  
5.2.2.  Dispensing Directions  .................................................................................................39  
5.2.3.  Dosing Information .....................................................................................................39  
Clinical Study Protocol: XPORT -CoV -1001 Selinexor  
Version 6.0  08 May 2020 
Confidential   Page 5 of 74 5.3. Missed or Vomited Doses of Selinexor  ......................................................................40  
5.3.1.  Missed Doses of Selinexor  .........................................................................................40  
5.3.2.  Vomited Doses of Selinexor .......................................................................................40  
5.4. Preparation/Handling/Storage/Accountability  ............................................................40  
5.5. Study Treatment Compliance .....................................................................................41  
5.6. Concomitant Medication  ............................................................................................41  
5.6.1.  Recommended Concomitant Treatments  ....................................................................41  
5.6.2.  Prohibited/Permitted Concomitant Medications  .........................................................41  
5.7. Dose Modifications  .....................................................................................................41  
6. DISCONTINUATION OF STUDY TREATMENT AND P ATIENT 
DISCONTINUATION/WITHDRAWAL  ..................................................................44  
6.1. Discontinuation of Study Treatment ...........................................................................44  
6.2. Patient Discontinuation/Withdrawal from the Study  ..................................................[ADDRESS_209261] to Follow up ........................................................................................................44  
6.4. Blinding ......................................................................................................................45  
6.5. Early Termination of the Study ..................................................................................45  
6.6. End of Study ...............................................................................................................45  
7. STUDY ASSESSMENTS AN D PROCEDURES  ......................................................46  
7.1. Baseline Assessments .................................................................................................46  
7.1.1.  Demographics .............................................................................................................46  
7.1.2.  Medical History  ..........................................................................................................46  
7.1.3.  Disease History  ...........................................................................................................46  
7.2. Effic acy Assessments .................................................................................................46  
7.3. Safety Assessments .....................................................................................................46  
7.3.1.  Physical Examinations ................................................................................................46  
7.3.2.  Ordinal Score  ..............................................................................................................47  
7.3.3.  Electrocardiograms  .....................................................................................................47  
7.3.4.  Clinical Safety Laboratory Assessments  ....................................................................48  
7.3.5.  Adverse Events and Serious Adverse Events .............................................................48  
7.4. Pharmacokinetic Assessments  ....................................................................................49  
7.5. Cytokine Assessments ................................................................................................49  
7.6. Leukocyte Phenotypi[INVESTIGATOR_007] ..............................................................................................49  
7.7. Viral  Assessments  ......................................................................................................49  
Clinical Study Protocol: XPORT -CoV -1001 Selinexor  
Version 6.0  08 May 2020 
Confidential   Page 6 of 74 8. ADVERSE  EVENTS  ..................................................................................................50  
8.1. Information on Reporting Adverse Events .................................................................50  
8.1.1.  Definitions  ..................................................................................................................50  
8.1.2.  Recording of Adverse Events .....................................................................................51  
8.1.3.  Adverse Event Causality  .............................................................................................52  
8.2. Serious Adverse Events  ..............................................................................................53  
8.3. Procedures for Handling Special Situations ...............................................................54  
8.3.1.  Pregnancy and Breastfeeding .....................................................................................54  
8.3.2.  Abuse, Misuse, Medication Errors and Overdose  ......................................................55  
9. STATISTICAL CONSIDER ATIONS  .......................................................................57  
9.1. General Considerations  ...............................................................................................57  
9.1.1.  Procedures for Handling Missing Data .......................................................................57  
9.2. Sample Size Determination  ........................................................................................57  
9.3. Populations for Analyses  ............................................................................................57  
9.4. Statistical Analyses  .....................................................................................................57  
9.4.1.  Efficacy Analyses  .......................................................................................................57  
9.4.2.  Safety Analyses  ..........................................................................................................58  
9.4.3.  Pharmacokinetic Analysis  ..........................................................................................59  
9.4.4.  Pharmacodynamic Analysis  ........................................................................................59  
9.4.5.  Viral Analysis  .............................................................................................................59  
9.5. Criteria for Stoppi[INVESTIGATOR_178144] ...................................................................................59  
9.6. Interim Analyses  .........................................................................................................60  
10. SUPPORTING DOCUMENTATION AND OPERATIONAL  
CONSIDERATIONS  ..................................................................................................61  
10.1.  Ethical and Administrative Obligations  ......................................................................61  
10.1.1.  Regulatory and Ethical Considerations  ......................................................................61  
10.1.2.  Responsibilities of the Investigator and Good Clinical Practice  ................................61  
10.2.  Financial Disclosure  ...................................................................................................61  
10.3.  Informed Consent Process ..........................................................................................61  
10.4.  Data Collection and Management  ..............................................................................63  
10.4.1.  Data Confidentiality  ....................................................................................................63  
10.4.2.  Site Monitoring ...........................................................................................................63  
10.4.3.  Data Collection  ...........................................................................................................64  
Clinical Study Protocol: XPORT -CoV -[ADDRESS_209262] u d y Pr ot oc ol: X P O R T -C o V -1 0 0 1  Seli ne x or  
Versi o n 6. 0   0 8 Ma y 2 0 2 0  
C o nfi de ntial   Pa ge 8 of 7 4      LI S T O F T A B L E S  
Ta ble 1:  Sc he d ule of Assess me nts f or a d mitte d patie nts o nl y  .................................................. 2 2  
Ta ble  2:  Sc he d ule of Assess me nt P ost - Disc har ge Peri o d f or O ut patie nts O nl y  ...................... 2 4  
Ta ble  3:  St u d y Treat me nt A d mi nistere d  ................................................................................... 3 9  
Ta ble  4:  Seli ne x or D ose M o dificati o n Ste ps f or A d verse Reacti o ns  ....................................... 4 1  
Ta ble  5:  Seli ne x or D osa ge M o dificati o n f or A d verse Reacti o ns ............................................. 4 2  
Ta ble  6:  Cli nical Safet y La b orat or y Tests  ................................................................................ 4 8  
Ta ble 7:  A d verse E ve nt ( A E) Pr ofile of L o w D ose ( ≤ 2 0 m g) Seli ne x or fr o m P hase [ADDRESS_209263] or y He mat ol o gic a n d S oli d T u m or 
Mali g na ncies . .............................................................................................................. 7 3  
 LI S T O F FI G U R E S  
Fi g ure 1:  Seli ne x or I n hi bits I n Vitr o S A R S - C o V 2 Viral Pr o pa gati o n ....................................... 2 7  
Fi g ure 2:  Se psis M o del f or Seli ne x or.  ........................................................................................ 2 9  
Fi g ure 3:  Effect of Seli ne x or i n E n d ot o xi n ( L P S)- I n d uce d Se psis a n d Deat h i n Mice.  ............ [ADDRESS_209264] u d y Pr ot oc ol: X P O R T -C o V -[ADDRESS_209265] u d y Pr ot oc ol: X P O R T -C o V -[ADDRESS_209266] researc h or ga nizati o n  
C R P C- reacti ve pr otei n  
Ctr o u g h  tr o u g h plas ma c o nce ntrati o n  
C R M 1 c hr o m os o me re gi o n mai nte na nce 1 (als o calle d e x p orti n 1)  
D R  deat h rate  
D S M B  Data Safet y M o nit ori n g B oar d  
e C R F electr o nic case re p ort f or m  
E C G Electr ocar di o gra m  
E D C  electr o nic data ca pt ure  
E C M O e xtrac or p oreal me m bra ne o x y ge nati o n  
F D A  F o o d a n d Dr u g A d mi nistrati o n  
G- C S F gra n ul oc yte -c ol o n y sti m ulati n g fact or  
G C P  g o o d cli nical practice  
h C G h u ma n c h ori o nic g o na d otr o pi n  
HI P A A  Healt h I ns ura nce P orta bilit y a n d Acc o u nta bilit y Act  
I A i nteri m a nal ysis  
I C F i nf or me d c o nse nt f or m  
I E C I n de pe n de nt Et hics Co m mittee  
I L Interle u ki n  
I R B I nstit uti o nal Re vie w Boar d  
I κ B   i n hi bit or of n uclear fact or -ka p pa b ( nf -κb)  
I N Fγ  i nterfer o n- γ 
I P i n vesti gati o nal pr o d uct  C CI 
Clinical Study Protocol: XPORT -CoV -1001 Selinexor  
Version 6.0  08 May 2020 
Confidential   Page 11 of 74 ITT intent-to -treat  
LPM  liters per minute  
MCP-1 monocyte chemoattractant protein 1  
MIF-1α  macrophage inflammatory protein 1α  
MM multiple myeloma  
MODS  multiple organ dysfunction syndrome 
MW molecular weight  
NCI CTCAE  National Cancer Institute Common Terminology Criteria for Adverse Events  
NES  nuclear export sequence  
NF-κB nuclear factor κ b 
NG Nasogastric  
NHBE  normal human bronchial epi[INVESTIGATOR_178145] -inflammatory drugs  
OSI Ordinal Scale for Clinical  Improvement   
PEG  percutaneous endoscopic gastrostomy  
PFS progression-free survival 
PHI protected health information 
PPARγ  peroxisome proliferator -activated receptor γ  
PR partial response  
QoD every other day  
RNA  ribonucleic acid  
RNP  Ribonucleoprotein 
RRMM relapsed/refractory multiple myeloma  
RSV respi[INVESTIGATOR_178146] u d y Pr ot oc ol: X P O R T -C o V -[ADDRESS_209267] or -α 
T T CI  ti me t o cli nical i m pr o ve me nt  
U L N  u p per li mit of n or mal  
v R N P  viral ri b o n ucle o pr otei n  
W H O  W orl d Healt h Or ga nizati o n  
X P O 1  e x p orti n 1 (als o calle d C R M 1) 
 C CI 
Clinical Study Protocol: XPORT -CoV -1001 Selinexor  
Version 6.0  08 May 2020 
Confidential   Page 13 of 74 SYNOPSIS  
Sponsor:  
Karyopharm Therapeutics Inc. Investigational Product:  
Selinexor  (XPOVIO®, KPT -330) Study Phase:  
Phase 2 
Title of Study: A Phase 2 Randomized Single -Blind Study to Evaluate the Activity and Safety of Low 
Dose Oral Selinexor (KPT -330) in Patients with Severe COVID-19 Infection  
Protocol Number: XPORT -CoV-1001  
Study Name:  [CONTACT_178213] -CoV-1001  
Study Location:  
Approximately 4 0 international sites are planned.  
Study Rationale:  
Coronavirus disease 2019 ( COVID-19) is caused by [CONTACT_178176][INVESTIGATOR_6507] 2 ( SARS -CoV2 ) and can be accompanied by a marked inflammatory 
response, which is believed to be severely detrime ntal to the patient  and associated  with multi-organ 
dysfunction,  respi[INVESTIGATOR_42679]  (Lai 2020). Both the SARS-CoV2 lifecycle and pro -
inflammatory transcription factors require functional host nuclear export mediated by [CONTACT_178177] 1 ( XPO1 , 
also called CRM1 , OMIM 6025 59). XPO1 was recently identified as a “hub” host protein for SARS-
CoV viral propagation (Zhou 2020) . Inhibition of XPO1 by [CONTACT_178178] 
(SINE ) compound  selinexor could induce  both anti -viral and anti -inflammatory activities. 
Selinexor  (XPOVIO®, KPT -330) is a potent, oral, slowly reversible covalent SINE compound that 
specifically inhibits  XPO1 . XPO1 mediates the nuclear export of proteins and ribonucleoprotein (RNP) 
complexes carrying a leucine-rich nuclear export sequence (NES)  (Behrens 2017). Over [ADDRESS_209268] been identified including proteins with regulatory roles in the  inflammatory 
response and many  viral proteins including SARS -CoV proteins . In a recent study, selinexor was shown 
to potently inhibit SARS-CoV2 viral propagation in Vero cells with IC 50 and IC 90 of <10nM and 100nM , 
respectively.  
Selinexor  received accelerated approval from the FDA in July 2019 in combination with dexamethasone 
as a treatment for patients with  advanced  multiple myeloma  (MM). The approved dose of  selinexor for 
advanced MM is 160 mg per week (80 mg PO  twice weekly ). Over [ADDRESS_209269] received selinexor alone or in combination with other anti -neoplastic agents in 
clinical studies ; nearly [ADDRESS_209270] common side 
effects at these high doses, namely nausea, emesis, anorexia, low sodium and low platelets are dose 
dependent and reversible  (Gavriatopoulou 2020).  
Selinexor was initially evaluated in  two Phase 1 dose escalation studies in patients with advanced 
heavily pretreated hematologic (KCP - 330-001) and solid tumors (KCP - 330-002). These patients h ad 
multiple lines of prior chemotherapy and were severely immunocompromised frail patients with heavily pre-treated relapsed refractory hematologic and solid tumors.  Selinexor at doses of ≤12 mg/m
2 (~20 mg) 
demonstrated target engagement in patients’ tumor biopsies as assessed by [CONTACT_178179]1 
cargoes such as Iκ B and FOXO1 (pre- and 2-[ADDRESS_209271] -treatment biopsies)  (Razak 2016; 
Karyopharm Data on File). Durable anti -tumor activity was observed in patients with both advanced 
hematological and solid tumors was observed at doses of ≤12 mg/m2, despi[INVESTIGATOR_178147], heavily pretreated neoplasms that were refractory to available anti -cancer agents 
(Kuruvill a 2017; Garzon 2017; Razak 2016). 
At a dose ≤12 mg/m2 (~20 mg) in the first [ADDRESS_209272] common non-hematologic adverse events 
(AEs) were low grade (Grade 1 and 2) nausea, decreased appetite , fatigue, vomiting and dysgeusia, that 
Clinical Study Protocol: XPORT -CoV -1001 Selinexor  
Version 6.0  08 May 2020 
Confidential   Page 14 of 74 was manageable with supportive care. Hematologic AEs included only thrombo -cytopenia, and the 
Grade 3 and 4 events (1 each) were observed in patients with refractory hematologic cancers (acute 
leukemia and MM) ( Appendix 2). There were no clinically significant changes in serum chemistries. 
Nearly all of the adverse events were reversible and responded to supportive care.  Finally, there were no 
clinically significant drug- drug interactions  at these low doses, nor were any observed at much higher 
doses.  Based on these results, the dose of 20 mg three times per week (60 mg per week) used here is 
anticipated to be well tolerated based on two phase 1 clinical studies (and detailed in Appendix 2) and to 
confer both anti -viral and anti -inflammatory activity as described below.  
A variety of viruses produce proteins that require nuclear export to carry out their functions. SARS -
CoV2 proteins, including nucleoprotein (N), protein 9b, Orf6 and potentially spi[INVESTIGATOR_2531] (S) and envelop (E) proteins, utilize XPO1 to properly function. Amongst >[ADDRESS_209273] proteins, XPO1 and three other “hub” proteins have the highest number of functional connections with SARS -CoV pro teins  (Zhou 
2020). Inhibition of XPO1 by [CONTACT_178180]1 inhibitor leptomycin B results in apoptosis of 
the SARS -CoV-infected host cells and might prevent SARS -CoV inhibition of innate immunity as well 
as the marked viral-induced pro-inflammatory effects that lead to COVID-19 (Jorquera 2018). SINE 
compounds, including selinexor and the closely related analog verdinexor, block XPO1 in a fashion 
similar to  that of leptomycin B, are taken orally and have been shown to be tolerated in humans. 
Recently, selinexor was ranked 18 out of > 400 drugs screened for ability to regulate SARS -CoV gene 
expression.  The ability of selinexor  to inhibit SARS-CoV2 viral propagation was evaluated in vero cells 
using two approaches: (a) prophylactic (pre -treatment) of cells with selinexor prior to infection and (b) 
concurrent treatment with selinexor at the time of infection (co -incubation). Pretreatment or co -
incubation of  selinexor resulted in significant inhibition of  viral propagation with IC
50 of ~10 nM and 
the IC 90 of ~100 nM.   The cytokine profile observed in COVID-19 corelates with disease severity and is 
characterized by [CONTACT_178181] (IL) -2, IL -7, granulocyte -colony stimulating factor (G -CSF), 
interferon-γ (INFγ) inducible protein 10, monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1α (MIF-1α), and tumor necrosis factor-α (TNFα) (Huang 2020). In 150 cases in Wuhan, China, independent predictors of fatality included elevated IL -6 levels (p<0 .0001)  (Ruan 2020) . 
Host cell factors are required for the replication of all viruses. However,  pharmacological manipulation 
of host cell factors, as a means of inhibiting viral replication,  has not yet been realized.  Preclinical data 
demonstrate that  verdinexor  and other SINE compounds  have  activity against >20 viruses, including the 
single stranded RNA viruses respi[INVESTIGATOR_4345] (RSV)  and influenza , along with other common 
causes of  respi[INVESTIGATOR_4416]. Specifically, verdinexor  disrupts the viral replication cycle by [CONTACT_178182] (vRNP) with the XPO1 nuclear export protein.  
Additionally,  SINE compounds  reduce inflammation through inhibition of the NF -κB pathway and 
nuclear retention and activation of  anti-inflammatory  targets such as IκB, RXRα, and  PPARγ (Tajiri 
2016; Kashyap 2016; Widman 2018) . This leads to reductions in cytokines including IL -1, IL -6 and, 
TNFα.  In a model that is relavant to severe COVID- 19 with respi[INVESTIGATOR_5448], selinexor was 
evaluated in a mouse model of sep sis and ARDS utilizing an intraperitoneal injection of a lethal dose of 
bacterial endotoxin (LPS). In this sepsis model, selinexor given via oral gavage administered 30 minutes after the lethal dose of endotoxin treatment increased survival at a dose of ≥1 5 mg/m
2 (Wu 2018). 
Influenza and SARS -CoV infection induce marked host inflammatory responses, and there are 
predictive animal models of influenza infection. We have therefore investigated the effect of XPO1 
blockade by  [CONTACT_178183], replication, pathology and mortality 
in animal and  in vitro  models of influenza  (Perwitasari 2016 ). Treatment with  verdinexor  leads to 
marked nuclear accumulation of  vRNP  and inhibition of influenza replication. Broad-spectrum anti -
influenza activity with nanomolar potency was observed with  verdinexor  against a variety 
of both influenza A and B strains in vitro  (Perwitasari 2016). In vivo , oral treatment with  verdinexor 
showed anti -influenza activity in mouse and ferret models of influenza infection . Verdinexor  reduced 
viral burden in the lung, inhibited  pro-inflammatory cytokine induction and reduced virus -associated 
Clinical Study Protocol: XPORT -CoV -1001 Selinexor  
Version 6.0  08 May 2020 
Confidential   Page 15 of 74 lung pathology and  pulmonary inflammation in infected animals.  Verdinexor  was also effective in 
delaying mortality and improving survival in mice challenged with a lethal infection of influenza virus, 
even when given 4 days after  the initiation of infection ( Perwitasari 2016 ). Given the similarities in the 
inflammatory processes associated with SARS -CoV and influenza viruses, these  results suggest that 
such beneficial effects may also be observed  with SINE compounds in patients with COVID- 19. 
Selinexor (MW 443.3) and verdinexor (MW 442.3) are closely related molecules that differ by [CONTACT_178184]. They have similar chemical, pharmacological , and pharmacokinetic properties  including similar 
oral bioavailability . Both are potent (Ki < 10 nM) and highly selective inhibitors of XPO1. Both 
compounds form slowly reversible covalent bonds with cysteine-528 of XPO1 leading to its inactivation, 
and both are orally bioavailable compounds with no known drug-drug interactions  (Appendix 2 ). 
Selinexor has been most intensively studied in cell lines and preclinical models of neoplastic diseases, 
whereas verdinexor has been studied most intensively in viral and autoimmune disorders. Selinexor is 
approved for treatment  in patients with advanced refractory MM  at a high dose of [ADDRESS_209274] availability including a commercial 
supply of selinexor tablets, this study will be initiated with selinexor.  As describ ed above, there are no 
known chemical, pharmacological , or toxicological distinctions between the two agents that would favor 
verdinexor at this time given the emergent SARS -CoV2 pandemic. Based on the pharmacokinetics of 
selinexor and verdinexor, low dose s (e.g., 20 mg per dose) of these agents are anticipated to deliver 
sufficient drug to confer both anti -viral and anti -inflammatory activity in patients with viral infections, 
including the SARS-CoV2 virus.  
Hypothesis: Oral selinexor  + standard of  care ( SoC) will expedite the recovery, suppress the viral load, 
shorten the hospi[INVESTIGATOR_178148]-19 
compared to placebo  + SoC. 
Objectives and Endpoints:  Low dose oral selinexor (20 mg on QoD each week)  + SoC will expedite 
the clinical recovery, suppress the viral load, shorten the hospi[INVESTIGATOR_178149]-19 compared to  placebo  + SoC. 
Objectives  Endpoints  
Primary Objectives  
Day 14 Ordinal Scale Improvement  (OSI) Proportion of patients with at least a 2 point 
improvement (increase) in the Ordinal Scale from 
baselineto  Day 14. 
The Ordinal S cale is an assessment of the clinical 
status at the first assessment on each day of hospi[INVESTIGATOR_059]. 
The scale is as follows:  
1. Death;  
2. Hospi[INVESTIGATOR_057], on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO);  
Clinical Study Protocol: XPORT -CoV -1001 Selinexor  
Version 6.0  08 May 2020 
Confidential   Page 16 of 74 3. Hospi[INVESTIGATOR_057], on non -invasive ventilation or 
high flow oxygen devices;  
4. Hospi[INVESTIGATOR_057], requiring supplemental oxygen;  
5. Hospi[INVESTIGATOR_9651], not requiring supplemental 
oxygen - requiring ongoing medical care 
(COVID-19 related or otherwise);  
6. Hospi[INVESTIGATOR_057], not requiring supplemental 
oxygen - no longer requires ongoing medical 
care;  
7. Not hospi[INVESTIGATOR_057], limitation on activities and/or 
requiri ng home oxygen;  
8. Not hospi[INVESTIGATOR_057], no limitations on activities.  
Key Secondary Objectives  
To evaluate improvement in clinical 
measures across the 2 treatment arms  • Time to recovery defined as  improvement from 
baseline score of 3 to ≥4 or from a baseline  score 
of 4 to ≥5  
• Proportion of patients with at least a 2 point 
improvement (increase) in the Ordinal Scale from 
baseline to Day 7. 
• Proportion of patients with at least a 1 point 
improvement (increase) in the Ordinal Scale from 
baseline to  Day 7 
• Proportion of patients with at least a 1 point 
improvement (increase) in the Ordinal Scale from 
baseline to Day 14.  
• Time to an improvement of  2 point using WHO 
Ordinal Scale Improvement (TTCI-2)  
• Time to c linical i mprovement  (TTCI-1): defined as 
the time from randomization to an improvement of 
1 point on the  Ordinal S cale 
• Overall death rate on Day 28  
• Rate of mechanical ventilation  
Additional Secondary Objectives  
To evaluate improvement in additional clinical measures across the 2 treatment arms   • Overall Survival  
• Overall death rate on D ay 14  
• Rate of ICU admission  
• Length of hospi[INVESTIGATOR_059]  
• Length of ICU stay  
Cli nical St u d y Pr ot oc ol: X P O R T -C o V -1 0 0 1  Seli ne x or  
Versi o n 6. 0   0 8 Ma y 2 0 2 0  
C o nfi de ntial   Pa ge 1 7  of 7 4  • D urati o n of mec ha nical ve ntilati o n  
• Pa O 2: Fi O 2 a n d/ or o x y ge nati o n i n de x o ver ti me  
T o deter mi ne t he a nti -i nfla m mat or y a n d 
i m m u ne effect of seli ne x or  • Re d ucti o n of C -reacti ve pr otei n ( C R P)  
• Re d ucti o n i n ferriti n le vels  
• L D H  
• Meas ure c ha n ges  fr o m baseli ne of bl o o d plas ma 
c yt o ki nes: I L -1 β, I L -1 R α, I L -2, I L -4, I L -5, I L -6, 
I L- 7, I L -8, I L -9, I L -1 0, I F Nγ, I P 1 0, T N F α   
T o assess safet y a n d t olera bilit y of seli ne x or 
[ti me  fra me: u p t o 2 8 da ys]  • Listi n g a n d d oc u me ntati o n of fre q ue nc y a n d 
se verit y of a d verse effects  
T o c haracterize seli ne x or p har mac o ki netics  • Seli ne x or P K para meters, ma xi m u m plas ma 
c o nce ntrati o n ( C ma x ) a n d tr o u g h c o nce ntrati o n 
( C tr o u g h ), if feasi ble  
E x pl or at or y E n d p oi nts  
 
O ver all St u d y Desi g n:   
T his is a ra n d o mize d phase [ADDRESS_209275] of h os pi[INVESTIGATOR_18552] d patie nts ≥ 1 8  y ears ol d wit h CO VI D -1 9 . 
T he e nr oll me nt will be stratifie d b y : 
• Use of c o nc o mita nt t hera pi[INVESTIGATOR_014]: a n a nti -viral (e. g. , re m desi vir ) or a n  a n ti -i nfla m mat or y  ( e. g. 
h y dr o x y c hl or o q ui ne , bi ol o gics tar geti n g e . g., I L- 6 or I L - 1). N ote: aceta mi n o p he n a n d  
n o nster oi dal a nti -i nfla m mat or y dr u gs ( N S AI Ds ) will n ot c o nstit ute a nti -i nfla m mat or y a ge nts  f or 
t he p ur p oses of stratificati o n .  
• Hi g h Ris k C o m or bi dities : A ge > 7 5, B MI > 3 0 ,  ca ncer  p atie n ts o n c he m ot hera p y, patie nts wit h 
car diac  ( C A D, A MI, C H F)  or  p ul m o nar y ( C O P D, e m p h yse ma)  disease   dia betes, h y perte nsi o n ). 
Stratificati o n will be base d o n n u m ber of hi g h ris k c o m or bi dities:  ( 1  vs   ≥2  vs  0)  
A d ose of [ADDRESS_209276] b o will be a d mi nistere d orall y o n Da ys 1, 3, a n d 5 of eac h 
wee k f or u p t o 2 wee ks. If t he patie nt is t olerati n g t hera p y a n d cli nicall y be nefitti n g (i .e., n ot meeti n g C CI 
Cli nical St u d y Pr ot oc ol: X P O R T -C o V -[ADDRESS_209277] o p pi n g t hera p y liste d bel o w), d osi n g ca n c o nti n ue f or a n a d diti o nal 2 wee ks ( o n 
Da ys 1 5, 1 7, 1 9, 2 2, 2 4, a n d 2 6).  
Patie nts w h o ac hie ve A N Y of t he f oll o wi n g criteria will be c o nsi dere d as ha vi n g cli nical be nefit f or t he 
p ur p ose of c o nti n ui n g d osi n g f or a n a d diti o nal 2 wee ks.  
1.  Patie nt s w h o  re mai ns h os pi[INVESTIGATOR_18552] d a n d:  
a.  Has n ot ha d a seli ne x or -relate d Gra de 4 A E or seli ne x or -relate d seri o us A E ( S A E)  
A N D  
b.  Has n ot ha d > 1 p oi nt  or di nal sc ore re d ucti o n ( w orse ni n g)  
O R  
c.  Has 2 p oi nt  re d ucti o n ( w orse ni n g) i n or di nal sc ore wit h a ≥ 2 0 % a bs ol ute re d ucti o n i n 
Fi O [ADDRESS_209278] meet t he f oll o wi n g criteria i n or der t o 
c o nti n ue o n seli ne x or:  
a.  Platelet c o u nt > 7 5, 0 0 0/ m m 3 a n d  
b.  Ne utr o p hil c o u nt > 1, 0 0 0/ m m 3 a n d  
c.  Ser u m s o di u m > 1 3 0  m m ol/ L a n d  
d.  N o Gra de ≥ [ADDRESS_209279] at disc har ge  
N u m ber of P atie nts ( pl a n ne d):  
A p pr o xi matel y 3 0 0 patie nts will be e nr olle d o verall as f oll o ws:  
a.  ~ 5 0 patie nts i n Pr ot oc ol versi o n ≤ 5. [ADDRESS_209280] u d y P o p ul ati o n: P atie nts m ust  f ulfill criteri a t o be eli gi ble f or e nr oll me nt i n t he st u d y  
Eli gi ble p atie nts are a d ult s ≥[ADDRESS_209281]  pr o vi de si g ne d  writte n  or ver bal  i nf or me d c o nse nt. T he 
I nf or me d C o nse nt F or m (I C F) a n d t he pr ocess t o o btai n t he i nf or me d c o nse nt will c o m pl y wit h all l ocal 
la ws, re g ulati o ns, a n d g ui da nce.  
I ncl usi o n Criteri a:  
Patie nts are eli gi ble t o be i ncl u de d i n t he st u d y o nl y if t he y meet all t he f oll o wi n g criteria:  
1.  A ge ≥ 1 8 y ears  
2.  C o nfir me d l a b orat or y dia g n osis of  S A R S -C o V 2 b y sta n dar d F D A -a p pr o ve d R T -P C R assa y or 
e q ui vale nt F D A -a p pr o ve d testi n g (l ocal la bs)  wit hi n 7 da ys of e nr oll me nt  
3.  C urre ntl y h os pi[INVESTIGATOR_18552] d  
4.  I nf or me d c o nse nt  C CI 
Clinical Study Protocol: XPORT -CoV -1001 Selinexor  
Version 6.0  08 May 2020 
Confidential   Page 19 of 74 5. Has symptoms of severe COVID -19 as demonstrated by:  
a. At least 1 of the following: fever, cough, sore throat, malaise, headache, muscle pain, 
shortness of breath at rest or with exertion, confusion, or symptoms of severe lower 
respi[INVESTIGATOR_178150]  
b. Clinical signs indicative of lower respi[INVESTIGATOR_178151]- 19, with at least one of 
the following: SaO
2 <92% on room air in last 12 hours or requires  ≥4 LPM  oxygen by [CONTACT_178185], non-rebreather/ Ventim ask (or similar device) or high flow nasal canula in order to 
maintain SaO 2 ≥92%,  PaO 2/FiO 2 <300 mm/hg. P atients with COPD or chronic lung disease 
must demonstrate  evidence  of increased oxygen needs above baseline. 
6. Elevated CRP  > [ADDRESS_209282] 
7. Concurrent anti -viral and/or anti -inflammatory agents (e.g., biologics, hydroxychloroquine) are 
permitted. If in the physician’s judgement, it is in the best interest of the patient to use anti-viral 
or anti -inflammatory treatments, these treatments are to  be documented in the patient’s chart and 
entered in the electronic case report form.  
Note: Patients who may have received plasma convalescent therapy > [ADDRESS_209283] dose of study treatment. Highly effective methods of contraception are 
listed in Section  8.3.1. 
Exclusion Criteria:  
1. Evidence of critical COVID-19 based on:  
a. Respi[INVESTIGATOR_1399] (defined by [CONTACT_178186], oxygen 
delivered by [CONTACT_178187], or clinical diagnosis of respi[INVESTIGATOR_178152])  
b. Septic sh ock  (defined by [CONTACT_178188]) 
c. Multiple organ dysfunction/failure  
2. In the opi[INVESTIGATOR_871], unlikely to survive for at least 48 hours from screening.  
3. Inadequate hematologic parameters as indicated by [CONTACT_178189]:  
a. Patients with severe neutropenia (ANC <1000 x 109/L) or 
b. Thrombocytopenia (e.g., platelets <100,000 per microliter of blood ) 
4. Inadequate renal and liver function as indicated by [CONTACT_178190]:  
a. Creatinine clearance (C rCL) <20 mL/min using the formula of Cockcroft and Gault.  
b. Aspartate transaminase (AST) or alanine transaminase (ALT) > 5 x upper limit of normal  
5. Hyponatremia defined as sodium less than 13 0 mEq/L 
6. Unable to take oral medication when inform consent is obtained.  
7. Patients with a legal  guardian or who are incarcerated.  
Clinical Study Protocol: XPORT -CoV -[ADDRESS_209284] of prohibited strong CYP3A 
inhibitors and inducers is provided in Appendix 3.  
9. Pregnant and breastfeeding women . 
Study Treatment/Treatment Groups, Dose, and Mode of Administration:  
A dose of 20 mg selinexor or matching placebo will be administered orally on Days 1, 3, and 5 of each 
week for up to 2 weeks. If the patient is tolerating therapy and clinically benefitti ng, as defined below, 
dosing can continue for an additional 2 weeks (on Days 15, 17, 19, 22, 24, and 26 ). 
Duration of Treatment and Follow-up:  
Patients will receive study treatment  for up to 14 days . 
Dosing can continue for an additional 2 weeks if  ANY of  the following criteria are met: 
1. Patients who  remain hospi[INVESTIGATOR_178153] : 
a. has not had a selinexor -related Grade 4 Advese Event (AE) or selinexor -related Serious 
AE (SAE) AND  
b. has not had >1 point  ordinal score reduction (worsening)  OR  
c. has 2 point  reduction (worsening) in ordinal score with a ≥20% absolute reduction in 
FiO2 from peak oxygen requirement  
2. Patients discharged from the hospi[INVESTIGATOR_5107] [ADDRESS_209285] meet the following criteria to continue  
selinexor therapy : 
a. Platelet count > 75,000/mm3 and 
b. Neutrophil count >1, 000/mm3 and 
c. Serum sodium > 130 mmol/L and  
d. No Grade ≥[ADDRESS_209286] at discharge  
Note: patients discharged from the hospi[INVESTIGATOR_178154].  
Therapy will be stopped if any of the events defined below  occur prior to 28 days:  
• Patient withdraws consent to continue study treatment.  
• Worsening clinical condition defined as at least 5 days of intubation/ECMO with no 
evidence of clinical improvement.  Patients who are clinically stable based on oxygen 
requirements on mechanical ventilation will be permitted to remain on study.  
• Grade ≥3 nausea or vomiting despi[INVESTIGATOR_178155].  
• Progression of renal dysfunction requiring dialysis.  
• Grade [ADDRESS_209287] u d y Pr ot oc ol: X P O R T -C o V -[ADDRESS_209288] atistic al  Met h o ds:  
S a m ple Size C alc ul ati o n a n d St atistic al P o wer:  
A p pr o xi matel y 2 4 7 patie nts  
 
A n al ysis P o p ul ati o ns:  
T he i nte nt -t o -treat (I T T) p o p ulati o n will c o nsist of all patie nts w h o are ra n d o mize d i n t he st u d y  wit h 
c o nfir me d S A R S -C o V [ADDRESS_209289] u d y treat me nt.  
T he all -treat ( A T) p o p ulati o n will c o nsist of all patie nts w h o t o o k at least o ne d ose of st u d y treat me nt o n 
t his st u d y  a n d ha ve c o nfir me d S A R S -C o V 2 i nfecti o n .  
Effic ac y A n al yses:  
T he differe nce of t he pri mar y e n d p oi nt (Da y 1 4 O SI ) bet wee n treat me nt ar ms will be calc ulate d wit h a 
9 5 % c o nfi de nce i nter val ( CI). C o m paris o n of O SI rates bet wee n t he 2 treat me nt ar ms will be perf or me d 
usi n g t he C oc hra n -Ma ntel -Hae nszel ( C M H) test stratifie d b y t he ra n d o mizati o n stratificati o n fact ors. 
T he C M H esti mate of t he o d ds rati o a n d its 9 5 % CI a n d t he p -val ue f or testi n g t he treat me nt differe nce 
will be re p orte d.  
A nal yses of ot her efficac y e n d p oi nts will be s pe cifie d i n Secti o n 9. 4. 1  a n d  t he S A P.  
S afet y A n al yses:  
Safet y a nal yses will be base d o n t he re p orte d A Es a n d ot her safet y i nf or mati o n, s uc h as 1 2 -lea d 
electr ocar di o gra m ( E C G), cli nical la b orat or y assess me nts  i ncl u di n g he mat ol o g y, ser u m c he mistr y, vital 
si g ns a n d p h ysical e xa mi nati o n.  
Safet y a nal yses will be perf or me d usi n g t he A T p o p ulati o n.  
 C CI 
Cli nical St u d y Pr ot oc ol: X P O R T -C o V -1 0 0 1                       Seli ne x or  
Versi o n 6. 0                                                                                                                                                                                                               0 8 Ma y 2 0 2 0  
C o nfi de ntial        Pa ge 2 2  of 7 4  S C H E D U L E O F  A S S E S S M E N T S   
T a ble 1:  Sc he d ule of Assess me nts  f or a d mitte d p atie nts  o nl y  
Acti vit y/ Assess me nt  Scree ni n g D osi n g Peri o d  
 E n d- of -
Tre at me nt H os pit al 
Disc h ar ge S afet y 
F oll o w- 
U p / E n d 
of St u d y i 
 D -2 t o 
D 1  D 1  
± 1 d a y  D 3  
±1 d a y  D 5  
±1 d a y  D 8  
±1 d a y  D 1 0  
±1 d a y  D 1 2  
±1 d a y  D 1 5  
±1 d a y  D 1 9  
±1 d a y  D 2 2  
±1 d a y  D 2 6  
±1 d a y  D 1 4/ 2 8 a   
I nf or me d C o nse nt b X              
I ncl usi o n/ E xcl usi o n X              
De m o gra p hics X              
Me dical hist or y  X              
Disease Hist or y  X              
Vital si g ns  c X T wice dail y d uri n g H os pi[INVESTIGATOR_178156] y    
C o m plete P h ysical 
E xa m  X            X  
Pre g na nc y testi n g  
(per site g ui d eli ne ) X           X   
Or di nal Sc ore d X Dail y a n d t he da y after disc har ge  X  
1 2 -lea d E C G e X As cli nicall y i n dic ate d    
A B G ( Arterial Bl o o d 
Gas) l X As cli nicall y i n dic ate d    
C B C wit h differe ntial X X X X X  X X X X X  X  
P T. aP T T , I N R  X X X X X  X X  X X    
C o m plete ser u m 
c he mistr y X X X X X  X X X X X  X  
C- reacti ve pr otei n, 
Ferriti n, L D H f X X X X X  X X X X X    
C CI 
Clinical Study Protocol: XPORT -CoV -1001            Selinexor  
Version 6.0                                                                                                                                                                                                              08 May 2020 
Confidential      Page 23 of 74 a Patients will remain on therapy for up to 14 days (or 28 days based on treating physician discretion)  
b Refer to Section 10.1 for Informed Consent  
c Vital signs include respi[INVESTIGATOR_697], temperature, and oxygen saturation It is recommended to measure SpO 2 in the same position for each patient throughout the duration of the study  
d Ordinal Score ( Section 7.3. 2) will be assessed  at first assessment of day  
e For patients who had an ECG during the hospi[INVESTIGATOR_059], the ECG does not need to be repeated. Results of this most recent ECG should entered into the eCRF  
f Required study and should be performed unless hospi[INVESTIGATOR_178157], to be performed locally as available. Once 2 negative viral assessments are docu mented testing can be 
stopped. 
g Day 12 or Day 15 
h Blood samples (~ 2mL) for selinexor  PK will be collected at 4 ± 1 hr, 24 ± [ADDRESS_209290] selinexor dose on Day 1 and predose on Day 3 and Day 5. Details for PK sample collection and processing can 
be found in the Laboratory Manual.  
i This visit will occur 30 (+2) days post end of treatment and  may be performed as either a telephone call or an in -clinic visit. Only follow up on SAEs will be reported.  
j In order to minimize nausea, all patients should receive ondansetron [ADDRESS_209291] with 5 -HT3 antagonists.    
k I t is recommended that patients are dosed with study drug within 12 hours of consent  
l    If feasible. 
 
  
 
 Cells for Leukocyte 
Phenotypi[INVESTIGATOR_007]
f  X X   X  Xg X       
Selinexor or Placebok  X X X X X X (X) (X) (X) (X)    
Blood draws for 
selinexor PKh  X X X           
Cytokines X  X X X          
Adverse Events (any)  X Recorded Throughout  X  X 
Concomitant 
Medications  X Recorded Throughout  X   
5-HT3 antagonists  
Ondansetron or 
equivalentj  Daily as needed     
Survival Follow- up              X 
Cli nical St u d y Pr ot oc ol: X P O R T -C o V -1 0 0 1                     Seli ne x or  
Versi o n 6. 0                                                                                                                                                 0 8 Ma y 2 0 2 0  
C o nfi de ntial   Pa ge 2 4  of 7 4  T a ble  2: Sc he d ule of Assess me nt P ost -Disc h ar ge Peri o d f or O ut p atie nts O nl y  
Acti vit y/ Assess me nt a Sc he d ule  D a y [ADDRESS_209292] of Cli nical Trials o utli nes pr oce d ures t o be c o n d ucte d d uri n g t he C O VI D -1 9 pa n de mi c.  
b T his visit will oc c ur 3 0 ( + 2) da ys p ost e n d of treat me nt, a n d ma y be perf or me d as eit her a tele p h o ne call or a n i n cli nic vis it .  O nl y f oll o w o n 
S A Es will be re p orte d.  
c O nl y f or patie nts w h o are disc har ge d o n st u d y treat me nt  a n d w hile o n st u d y treat me nt . D ecisi o n t o c o nti n ue be y o n d da y 1 4 is per pr ot oc ol 
g ui deli nes 
 C CI 
Clinical Study Protocol: XPORT -CoV -1001               Selinexor  
Version 6.0                                                                                                                                                08 May 2020 
Confidential   Page 25 of 74 1. INTRODUCTION  
1.1. Study Rationale  
Novel coronavirus disease ( COVID-19) is caused by [CONTACT_178191] -CoV2  
(Cascella 2020 ).  The viral lifecycle requires interaction with >[ADDRESS_209293] proteins including 
exportin 1 (XPO1, also called CRM1).  Host inflammatory response to the virus can be marked, 
and poor outcomes are associated with high levels of pro-inflammatory cytokines. Selinexor, and the related compound verdinexor, are highly selective and potent oral inhibitor of XPO1 . In a 
recent study, selinexor was shown to potently inhibit SARS-CoV2 viral propagation in Vero 
cells with IC
50 and IC 90 of < 10nM and 100nM respectively ( see Section 1.3).  These SINE 
compounds have been shown block the interactions of several SARS- CoV and CoV2 proteins 
with XPO1, and separately to reduce pro- inflammatory cytokine levels through anti-
inflammatory transcriptional signaling.   
Dosing verdinexor with a delay of up to 4 days in an influenza model was as efficacious as   
initiation early in infection, which aligns well with the understood incubation period of the novel coronavirus ( Perwitasari 2016) . Verdinexor demonstrated activity against over 20 viruses, 
including respi[INVESTIGATOR_4345] (RSV), influenza, and other common causes of viral respi[INVESTIGATOR_4416]  (Jorquera 2018; Widman 2018) .  
Selinexor (MW 443.3) and verdinexor (MW 442.3) are closely related molecules that differ by [CONTACT_178192]. They have similar chemical, pharmacological and pharmacokinetic properties including oral bioavailability .  Both are potent (Ki < 10 nM) a nd highly selective inhibitors of 
XPO1 with no known drug-drug interactions. Selinexor is approved in the U.S. in combination with dexamethasone for the treatment of adult patients with relapsed refractory multiple myeloma (RRMM)  under the brand name [CONTACT_178214]® at doses of 160 mg per week (80 mg twice 
weekly). In this Clinical Trial, selinexor will be dosed at  20 mg three times per week (60 mg per 
week total). This selin exor dose is anticipated to be well tolerated without significant cytopenias 
and to induce both anti-viral and anti- inflammatory activities . 
1.2. Background on COVID-19 
In December 2019, a novel coronavirus (subsequently named SARS -CoV2 ) was detected in [ADDRESS_209294] commonly reported clinical symptom in laboratory- confirmed cases was  fever (88%), 
dry cough (68%), fatigue (38%), sputum production (33%), dyspnea (19%), sore throat (14%), headache (14%) and myalgia or arthralgia (15%). Less common symptoms we re diarrhea (4%) 
and vomiting (5%). About 80% of reported cases in China had mild to moderate disease (including non- pneumonia and pneumonia cases), 13.8% had severe disease  (as defined in this 
protocol) and 6.1% were critical (respi[INVESTIGATOR_13521] y failure, septic shock, and/or multiple organ 
dysfunction/failure). Current estimates suggest a median incubation period from [ADDRESS_209295] u d y Pr ot oc ol: X P O R T -C o V -1 0 0 1                     Seli ne x or  
Versi o n 6. 0                                                                                                                                                 0 8 Ma y 2 0 2 0  
C o nfi de ntial   Pa ge 2 6  of 7 4  setti n gs. Base d o n a lar ge dataset fr o m cases i n C hi na, t he o verall case fatalit y ris k ( C F R) a m o n g 
la b orat or y -c o nfir me d cases is c urre ntl y  ~ 0. 7 % f or patie nts wit h s y m pt o m o nset after [ADDRESS_209296] C F R  a m o n g pe o ple occ urs o ver 8 0 years of a ge ( 4 -1 5 %)  ( H ua n g 2 0 2 0 ; R ua n 
2 0 2 0 ). 
1. 2. 1.  Vir al She d di n g  a n d Tr a ns missi o n  
O ver t he c o urse of t he i nfecti o n, t he vir us has bee n i de ntifie d i n res pi[INVESTIGATOR_1305] y tract s peci me ns 1- [ADDRESS_209297] f or 7- 1 2 da ys i n m o derate cases a n d u p t o 2 
wee ks i n se vere cases. I n feces, viral R N A has bee n detecte d fr o m  da y 5 after o nset a n d u p t o 4 
t o 5 wee ks i n m o derate cases. T he vir us has bee n detecte d als o i n w h ole bl o o d, ser u m, sali va a n d 
uri ne. Pr ol o n ge d viral R N A s he d di n g has bee n re p orte d fr o m nas o p har y n geal s wa bs, u p t o 3 7 
da ys a m o n g a d ult patie nts a n d i n feces, f or m ore t ha n o ne m o nt h after i nfecti o n i n pe diatric 
patie nts. It s h o ul d be n ote d t hat viral R N A s he d di n g d oes n ot directl y e q uate wit h i nfecti vit y. 
1. 2. 2.  C yt o ki ne Le vels a n d O utc o mes  
C yt o ki ne le vels are  ass ociate d wit h CO VI D - 1 9 se verit y, c haracterize d b y i ncrease d i nterle u ki n 
(I L) -2, I L - 7, gra n ul oc yte-c ol o n y sti m ulati n g fact or ( G -C S F) , i nterfer o n- γ (I N Fγ) i n d uci ble 
pr otei n 1 0, m o n oc yte c he m oattracta nt pr otei n 1 ( M C P - 1) , macr o p ha ge i nfla m mat or y pr otei n 1 α, 
( MI F -1 α) a n d t u m or necr osis fact or -α ( T N F α)  ( H ua n g 2 0 2 0 ). 
Pre dict ors of fatalit y of 1 5 0 c o nfir me d C O VI D - 1 9 cases i n W u ha n i ncl u de d ele vate d I L- 6 le vels 
( p < 0· 0 0 0 1) ( R ua n 2 0 2 0 ). 
1. 3.  Sel i ne x or 
Seli ne x or ( X P O VI O ®, K P T -3 3 0) is a s mall m olec ule, oral, first -i n -class, p ote nt selecti ve 
i n hi bit or of X P O 1 -me di ate d n uclear e x p ort ( SI N E). It has  recei ve d accelerate d a p pr o val fr o m t he 
F D A i n J ul y 2 0 1 9 i n c o m bi nati o n wit h de xa met has o ne as a treat me nt f or patie nts 
wit h  a d va nce d m ulti ple m yel o ma  ( M M).  T he a p pr o ve d d ose of seli ne x or is 8 0 m g p o t wice 
wee kl y (t otal 1 6 0 m g per wee k). M ore t ha n [ADDRESS_209298] u dies, a n d ~ [ADDRESS_209299] c o m m o n si de 
effects at t hese hi g h  d oses , na mel y na usea, e mesis, a n ore xia, l o w s o di u m a n d l o w platelets are 
d ose de pe n de nt a n d re versi ble.  
T he a bilit y of seli ne x or t o i n hi bit viral pr o pa gati o n was e val uate d usi n g t w o a p pr oac hes: (a) 
pr o p h ylactic ( pre- treat me nt) of cells wit h seli ne x or pri or t o i nfecti o n a n d ( b) c o nc urre nt 
treat me nt wit h seli ne x or at t he ti me of i nfecti o n (c o -i nc u bati o n).  
C CI 
Cli nical St u d y Pr ot oc ol: X P O R T -C o V -1 0 0 1                     Seli ne x or  
Versi o n 6. 0                                                                                                                                                 0 8 Ma y 2 0 2 0  
C o nfi de ntial   Pa ge 2 7  of 7 4  L o w d ose seli ne x or : bi ol o gic al acti vit y, effic ac y a n d s afet y i n p atie nts wit h a d v a nce d c a ncer  
Seli ne x or was i nitiall y e val uate d i n [ADDRESS_209300] u dies i n patie nts wit h a d va nce d 
hea vil y pretreate d he mat ol o gic ( K C P - 3 3 0- 0 0 1) a n d s oli d t u m ors ( K C P- 3 3 0- 0 0 2). T hese 
patie nts ha d m ulti ple li nes of pri or c he m ot hera p y a n d were se verel y i m m u n oc o m pr o mise d frail 
patie nts wit h hea vil y pre -treate d rela pse d refract or y he mat ol o gic a n d s oli d t u m ors. Seli ne x or at 
d oses of ≤ 1 2 m g/ m 2 ( ~ 2 0 m g) de m o nstrate d tar get e n ga ge me nt i n patie nts’ t u m or bi o psies as 
assesse d b y n uclear l ocalizati o n of X P O 1 car g oes s uc h as I κB a n d F O X O 1 ( pre- a n d [ADDRESS_209301]-treat me nt bi o psies) ( Raza k 2 0 1 6 ; Kar y o p har m Data o n File). D ura ble a nti- t u m or acti vit y 
was o bser ve d i n patie nts wit h b ot h a d va nce d he mat ol o gical a n d s oli d t u m ors was o bser ve d at 
d oses of ≤ 1 2 m g/ m 2, des pi[INVESTIGATOR_040] t he fact t hat t hese patie nts ha d a d va nce d, hea vil y pretreate d 
ne o plas ms t hat were refract or y t o a vaila ble a nti -ca ncer a ge nts ( K ur u villa 2 0 1 7 ; Garz o n 2 0 1 7 ; 
Raza k 2 0 1 6 ).  
At a d ose ≤ 1 2 m g/ m 2 ( ~ 2 0 m g) i n t he first [ADDRESS_209302] c o m m o n n o n- he mat ol o gic 
a d verse e ve nts ( A Es) were l o w gra de ( Gra de 1 a n d 2) na usea, decrease d a p petite, fati g ue, 
v o miti n g a n d d ys ge usia, t hat was ma na gea ble wit h s u p p orti ve care. He mat ol o gic A Es i ncl u de d 
o nl y t hr o m b oc yt o pe nia, a n d t he Gra de 3 a n d 4 e ve nts ( 1 eac h) were o bser ve d i n patie nts wit h 
refract or y he mat ol o gic ca ncers (ac ute le u ke mia a n d m yel o ma)  ( A p pe n di x 2 ). T here were n o 
cli nicall y si g nifica nt c ha n ges i n ser u m c he mistries.  Nearl y all of t he a d verse e ve nts were 
re versi ble a n d res p o n de d t o s u p p orti ve care.  Fi nall y, t here were n o cli nicall y si g nifica nt dr u g- 
dr u g i nteracti o ns at t hese l o w d oses, n or were a n y o bser ve d at m uc h hi g her d oses. T he C ma x  wit h 
2 0 m g seli ne x or is 1 5 9 n g/ m L ( 3 5 9 n M).  Base d o n t hese res ults, t he d ose of 2 0 m g t hree ti mes 
per wee k ( 6 0 m g per wee k) use d here is a ntici pate d t o be well t olerate d base d o n t w o p hase [ADDRESS_209303] u dies ( detaile d i n A p pe n di x 2 ) a n d t o c o nfer b ot h a nti -viral a n d a nti -i nfla m mat or y 
acti vit y as descri be d bel o w.   C CI 
Clinical Study Protocol: XPORT -CoV -1001               Selinexor  
Version 6.0                                                                                                                                                08 May 2020 
Confidential   Page 28 of 74 Activity of Selinexor and other SINE compounds in models of Inflammation and Viral 
Infection   
Selinexor (MW 443.3) and verdinexor (MW 442.3) are closely related molecules that differ by 
[CONTACT_178192].  They have similar chemical, pharmacological and pharmacokinetic properties. Both 
are potent (Ki < 10 nM) and highly selective inhibitors of XPO1. Both compounds form slowly 
reversible covalent bonds with cysteine-[ADDRESS_209304] intensively in viral and autoimmune disorders ( Appendix 1).  
Over [ADDRESS_209305] been identified including proteins with regulatory roles in 
inflammatory response and many viral proteins including severe acute respi[INVESTIGATOR_6507] (SARS -CoV2) proteins ( Zhou 2020). 
A variety of viruses produce proteins that require  nuclear export to carry out their functions. 
SARS -CoV 2, including nucle oprotein (N), protein 9b, Orf6, and potentially spi[INVESTIGATOR_2531] (S) and 
envelop (E) proteins, utilize XPO1 to properly function ( Sharma 2011; Reed 2007). XPO1 and 
three other “hub” proteins have the highest number of functional connections with SARS- CoV 
proteins ( Gordon 2020). Inhibition of XPO1 by [CONTACT_178180]1 inhibitor leptomycin B 
results in apoptosis of the SARS -CoV-infected host cells and might prevent SARS- CoV 
inhibition of innate immunity as well as the marked viral-induced pro- inflammatory effects that 
lead to C OVID-19. SINE compounds, including selinexor and the closely related analog 
verdinexor, block XPO1 in a fashion similar to  that of leptomycin B, are taken orally and have 
been shown to be tolerated in humans. Recently, selinexor was ranked 18 out of 400 drugs screened for ability to regulate SARS -CoV gene expression analysis done by [CONTACT_178193] 
(private communication). 
Host cell factors are required for th e replication of all viruses.  However,  pharmacological 
manipulation of host cell factors, as a means of inhibiting viral replication, has not yet been 
realized.  Preclinical data demonstrate that  verdinexor and other SINE compounds have activity 
against >20 viruses, including respi[INVESTIGATOR_4345] (RSV), influenza and other common causes of respi[INVESTIGATOR_4416]. Specifically, verdinexor disrupts the viral replication cycle by [CONTACT_178194] (vRNP) with the XPO1 nuclear export protein  (Widman 2018; Perwitasari 201 6; Jorquera 2018).  
Additionally,  Selienxor and other SINEs  inhibit cytokine release i ncluding IL-1, IL -[ADDRESS_209306] and nuclear retention and activation of specific 
inhibitors of pro- inflammatory  transcriptional factors such as  IκB, RXRα, and  PPARγ
 (Tajiri 
2016; Kashyap 2016; Widman 2018)  In a model that is relavant  to severe COVID -19 with 
respi[INVESTIGATOR_5448],  selinexor was evaluated in a mouse model of sepsis and ARDS 
utilizing an intraperitoneal injection of a lethal dose of bacterial endotoxin (LPS). In this sepsis model, selinexor given via oral gavage administered 30 minutes after the lethal dose of endotoxin treatment increased survival at a dose of ≥15 mg/m
2 (Wu 2018; Figure 2 ). In addition, 
selinexor reduced inflammatory cytokine levels in the serum including TNFa, IL-6 and HMGB1 , 
while reducing the numbers of macrophages and polymorpho-nuclear neutrophils in th e mouse 
peritoneal cavity. Importantly, selinexor treatment attenuated the ARDS-like lung injury observed in this model. Details are provided in Appendix 1. 
Clinical Study Protocol: XPORT -CoV -1001               Selinexor  
Version 6.0                                                                                                                                                08 May 2020 
Confidential   Page 29 of 74 Figure 2:  Sepsis Model for Selinexor.  
Oral se linexor dosed 30 minutes after the induction of sepsis protected the mice and increased their survival (Figure 
2A). In addition, serum levels of the proinflammatory cytokines TNFa and IL-[ADDRESS_209307] LPS challenge were 
si
gnificantly lower in selinexor  treatment groups (Figure 2 B). 
 
As the severity of respi[INVESTIGATOR_178158]-19 is associated with the levels of cytokine 
secretion in SARS -CoV infected patients, the observed reductions in cytokine levels in this 
sepsis -ARDS model, as well as the resul ts in influenza described below, support the view that 
treatment of patients with COVID -19 (and other respi[INVESTIGATOR_4398])  with selinexor could be 
beneficial .  
Influenza and SARS- CoV infection s induce marked host inflammatory responses, and there are 
anima l models of influenza infection available. We have therefore investigated the effect of 
XPO1 blockade by [CONTACT_178195], replication, pathology 
and mortality in animal and in vitro  models of influenza. Treatment with  verdinexor leads to 
marked nuclear accumulation of vRNP  and inhibition of influenza replication. Broad- spectrum 
anti-influenza activity with nanomolar potency was observed with verdinexor against a variety of both influenza A and B strains in vitro  (Perwitasari 2016 ). Moreover, verdinexor exhibited 
anti-influenza activity  in vitro  in a model of viral replication in normal human bronchial 
epi[INVESTIGATOR_018] (NHBE) cells grown in a liquid -air interface, which is a model that mimics inf ection of 
the respi[INVESTIGATOR_178159].  In vivo, oral treatment with  verdinexor at 10-20 mg/kg 
showed anti-influenza activity in mouse and ferret models of influenza infection.  Verdinexor 
reduced viral burden in the lung, inhibited pro -inflammatory cytokine induction and reduced 
virus-associated lung pathology and pulmonary inflammation in infected animals. Verdinexor was also effective in delaying mortality and improving survival in mice challenged with a lethal infection of influenza virus, even when given [ADDRESS_209308] that such  beneficial  effects may also be observed in patients with C OVID-
19 (Perwitasari 2016).  
Given the urgency of the C OVID-[ADDRESS_209309] availability including a 
commercial supply of selinexor tablets, this study will be initiated with selinexor rather than 
verdinexor.  As described above, there are no known chemical, pharmacological or toxicological 
distinctions between the two agents that would favor verdinexor at this time given the emergent 
SARS -CoV2 pandemic. Based on the pharmacokinetics of selinexor and verdinexor, low doses 
(e.g., 20 mg per dose) of these agents are anticipated to deliver sufficient drug to confer both 
anti-viral and anti- inflammatory activity in patients with viral infections, including the SARS -
CoV2 virus. 

Clinical Study Protocol: XPORT -CoV -1001               Selinexor  
Version 6.0                                                                                                                                                08 May 2020 
Confidential   Page 30 of 74 Hypothesis   
Low dose oral selinexor (20 mg on QoD each week) will expedite the recovery, suppress the 
viral load, shorten hospi[INVESTIGATOR_059], and reduce mortality in patients with severe C OVID-[ADDRESS_209310] of care. 
1.4. Benefit/Risk Assessment  
Blockade of XPO1 has shown anti- SARS -CoV2 activity in vitro and anti- viral effects in animal 
models as well as in  influenza models . Severe influenza is associated with a pro -inflammatory 
cytokine profile similar to severe C OVID-19. Based on preclinical studies, inhibition of XPO1 is 
anticipated to confer both anti- SARS -CoV2 and anti- inflammatory activity at relatively low 
doses of selinexor to be used in this study. 
Higher doses of selinexor (160 mg per week) approved for use in the treatment of advanced 
RRMM  are associated with dose -dependent and generally revers ible nausea, fatigue, emesis, 
anorexia, low sodium and thrombocytopenia. The lower doses of selinexor used here (60 mg per week) are expected to achieve the relevant pharmacological concentrations. There are no known 
clinically significant drug -drug interactions with selinexor. The protocol allows concurrent use of 
other investigational anti -viral and/or anti -inflammatory agents. 
The highly selective and potent oral XPO1 inhibitors verdinexor and sel inexor have no 
pharmacologically important discernable differences. XPO1 inhibitors have activity in models of sepsis /ARDS , inflammation, and influenza . In a recent study selinexor demonstrated potent 
activity against SARS -CoV2  (IC
50= ~10 nM) . The adverse event profile of low dose selinexor 
consists of low grade, reversible and treatable symptoms ( Appendix 2). 
Therefore, we believe that the opportunity to confer both anti- viral and anti -inflammatory 
activity with a novel agent targeting a host protein warrants provides a positive risk /benefit assessment  in the treatment of severe C OVID-19.  
Clinical Study Protocol: XPORT -CoV -[ADDRESS_209311] a 2 point 
improvement (increase in the Ordinal Scale from 
baseline to Day 14. The Ordinal Score is an 
assessment of the clinical status at the first 
assessment on each day of hospi[INVESTIGATOR_059].  
The scale is as follows:  
1. Death;  
2. Hospi[INVESTIGATOR_057], on invasive mechanical 
ventilation or extracorporeal membrane 
oxygenation (ECMO);  
3. Hospi[INVESTIGATOR_057], on non- invasive 
ventilation or high flow oxygen 
devices;  
4. Hospi[INVESTIGATOR_057], requiring supplemental 
oxygen;  
5. Hospi[INVESTIGATOR_057], not requiring 
supplemental oxygen - requiring 
ongoing medical care (COVID -19 
related or otherwise);  
6. Hospi[INVESTIGATOR_057], not requiring 
supplemental oxygen - no longer 
requires ongoing medical care;  
7. Not hospi[INVESTIGATOR_057], limitation on 
activities and/or requiring home 
oxygen;  
8. Not hospi[INVESTIGATOR_057], no limitations on 
activities.   
Key Secondary O bjectives  
To evaluate improvement in clinical 
measures across the 2 treatment arms • Time to recovery defined as improvement 
from baseline score of 3 to ≥4 or from a 
baseline score of 4 to ≥5  
• Proportion of patients with at least a 2 point 
improvement (increase) in the Ordinal Scale 
from baseline to Day 7.  
Clinical Study Protocol: XPORT -CoV -1001               Selinexor  
Version 6.0                                                                                                                                                08 May 2020 
Confidential   Page 32 of 74 • Proportion of patients with at least a 1 point 
improvement (increase) in the Ordinal Scale 
from baseline to Day 7 
• Proportion of patients with at least a 1 point 
improvement (increase) in the Ordinal Scale 
from baseline to Day 14. 
• Time to an improvement of 2 point using 
WHO Ordinal Scale Improvement (TTCI-2) 
• Time to clinical improvement (TTCI -1): 
defined as the time from randomization to an improvement of 1 point on the Ordinal 
Scale  
• Overall Death Rate on Day 28 
• Rate of mechanical ventilation  
Additional Secondary Objectives  
To evaluate improvement in additional 
clinical measures across the 2 treatment 
arms   • Overall Survival 
• Overall death rate on Day 14 
• Rate of ICU admission  
• Length of hospi[INVESTIGATOR_059] 
• Length of ICU stay 
• Duration of mechanical ventilation 
• PaO 2:FiO 2 and/or oxygenation index  over 
time 
To determine the anti -inflammatory and 
immune effect of selinexor  • Reduction of C- reactive protein (CRP)  
• Reduction in ferritin levels  
• LDH  
• Measure changes from baseline of blood 
plasma cytokines: IL -1β, IL -1Rα, IL -2, IL-4, 
IL-5, IL- 6, IL -7, IL-8, IL-9, IL- 10, IFNγ, 
IP10, TNFα    
To assess safety and tolerability of 
selinexor [time  frame:  up to 28 days] • Listing and documentation of frequency and 
severity of adverse effects  
Cli nical St u d y Pr ot oc ol: X P O R T -C o V -1 0 0 1                     Seli ne x or  
Versi o n 6. 0                                                                                                                                                 0 8 Ma y 2 0 2 0  
C o nfi de ntial   Pa ge 3 3  of 7 4  T o c haracterize seli ne x or 
p har mac o ki netics • Seli ne x or P K para meters, ma xi m u m plas ma 
c o nce ntrati o n ( C ma x ) a n d tr o u g h 
c o nce ntrati o n ( C tr o u g h ), if feasi ble  
E x pl or at or y E n d p oi nts  
 C CI 
Clinical Study Protocol: XPORT -CoV -1001               Selinexor  
Version 6.0                                                                                                                                                08 May 2020 
Confidential   Page 34 of 74 3. STUDY DESIGN 
3.1. Overall Design  
This is a randomized phase 2 , single -blinded study of low dose selinexor ver sus placebo to 
evaluate the activity in patients with severe COVID-19.  
The study has 2 arms and will evaluate selinexor 20 mg + standard of care  (SoC) and placebo + 
SoC. As the treatment for COVID -19 is rapi[INVESTIGATOR_92311], the SoC will vary over time and across 
regions of the world. Therefore, SoC  may include antibiotics (e.g., azithromycin), anti- malarial 
(e.g., hydroxychloroquine), or anti virals (e.g. , remdesivir), and other agents (e.g., anti -IL-6 
antibodies) to be per the institution at each site. The randomization and stratification will 
minimize any influence in the variability of SoC. 
The study population will consist of hospi[INVESTIGATOR_9643] ≥18 years old with C OVID-19. 
The enrollment will be stratified b ased on cri teria in Section 4.4: 
Enrollment will be paused for evaluation of safety and efficacy after the enrollment of the first 
[ADDRESS_209312] 40 patients will be shared with the FDA prior to 
resuming enrollment. 
A dose of 20 mg selinexor or matching placebo will be administered orally on Days 1, 3, and 5 
of each week for up to 2 weeks. If the patient is tolerating therapy and clinically benefitting (i.e., 
not meeting any of the criteria for stoppi[INVESTIGATOR_178160]), dosing can continue for an 
additional 2 weeks (on Days 15, 17, 19, 22, 24, and 26).  It is recommended that patients are dosed with study drug within 12 hours of providing consent. 
Patients who achieve ANY of the following criteria will be considered as having clinical benefit 
for the purpose of continuing dosing for an additional 2 weeks. 
1. Patient remains hospi[INVESTIGATOR_82800]:  
a. Has not had a selinexor-related Grade 4 AE or selinexor- related serious AE (SAE)  
AND  
b. Has not had >1 point ordinal score reduction (worsening)  
OR  
c. Has 2 point reduction (worsening) in ordinal score with a ≥20% absolute 
reduction in FiO
[ADDRESS_209313] meet the following criteria in 
order to continue on selinexor: 
a. Platelet count >75,000/mm3 and 
b. Neutrophil count >1,000/mm3 and 
c. Serum sodium >130 mmol/L and 
d. No Grade ≥[ADDRESS_209314] u d y Pr ot oc ol: X P O R T -C o V -[ADDRESS_209315] n uclear e x p ort me diate d b y X P O 1. 
X P O 1 was rece ntl y i de ntifie d as a “ h u b” h ost pr otei n f or S R A S -C o V viral pr o pa gati o n  a n d 
seli ne x or has s h o w n mar ke d i n hi biti o n of viral re plicati o n i n vitr o  wit h a n I C 9 0  of ~ [ADDRESS_209316] patie nt has c o m plete d t he 3 0- da y Safet y f oll o w u p peri o d 
(after t heir last d ose of st u d y treat me nt), has wit h dra w n c o nse nt or has die d, w hic he ver c o mes 
first.   C CI 
Clinical Study Protocol: XPORT -CoV -1001               Selinexor  
Version 6.0                                                                                                                                                08 May 2020 
Confidential   Page 36 of 74 4. STUDY POPULATION  
Eligible p atients are adults ≥ [ADDRESS_209317]  provide signed  written or 
verbal informed consent. The Informed Consent Form (ICF) and the process to obtain the 
informed consent will comply with all local laws, regulations, and guidance. 
4.1. Inclusion Criteria  
Patients  are eligible to be included  in the study only if they meet all the following criteria:  
1. Age ≥[ADDRESS_209318] FDA -approved RT-qPCR 
assay or equivalent FDA -approved testing (local labs) within 7 days of enrollment. 
3. Currently hospi[INVESTIGATOR_057] . 
4. Informed consent. 
5. Has symptoms of severe C OVID-19 as demonstrated by: 
a. At least one of the following: fever, cough, sore throat, malaise, headache, muscle 
pain, shortness of breath at rest or with exertion, confusion, or symptoms of severe lower respi[INVESTIGATOR_178161] . 
b. Clinical signs indicative of lower respi[INVESTIGATOR_178151] -19, with at least 
one of the following: SaO2 <92% on room air in last 12 hours or requires  ≥4 LPM  
oxygen by [CONTACT_178196], non- rebreather/Ventimask (or similar device ) or high flow 
nasal canula in order to maintain SaO2 ≥92%, PaO2/FiO2 <300 mm/hg. Patients with COPD or chronic lung disease must demonstrate evidence of increased oxygen needs above baseline. 
6. Elevated CRP > [ADDRESS_209319] 
7. Concurrent anti -viral and/or anti- inflammatory agents (e.g., biologics, 
hydroxychloroquine) are permitted. If in the physician’s judgement, it is in the best interest of the patient to use anti -viral or anti- inflammatory treatments, these treatments 
are to be documented in the patient’s chart an d entered in the electronic case report form. 
 
Note: Patients who may have received plasma convalescent therapy > [ADDRESS_209320] dose of study treatment. Highly effective methods of contraception are listed in  Section  8.3.1. 
4.2. Exclusion Criteria   
Patient s are excluded from the study if any of the following criteria apply: 
Clinical Study Protocol: XPORT -CoV -1001               Selinexor  
Version 6.0                                                                                                                                                08 May 2020 
Confidential   Page 37 of 74 1. Evidence of critical C OVID-19 based on: 
a. Respi[INVESTIGATOR_1399] (defined by [CONTACT_178197] n and mechanical ventilation, 
oxygen delivered by [CONTACT_178187], or clinical diagnosis of 
respi[INVESTIGATOR_178162])  
b. Septic shock (defined by[CONTACT_178198] ) 
c. Multiple organ dysfunction/failure 
2. In the opi[INVESTIGATOR_871], unlikely to survive for at least 48 hours from screening  
3. Inadequate hematologic parameters as indicated by [CONTACT_178190]: 
a. Patients with severe neutropenia (ANC <1000 x 109/L) or 
b. Thrombocytopenia (e.g., platelets < 100,000 per microliter of blood) 
4. Inadequate renal and liver function as indicated by [CONTACT_178190]: a. Creatinine clearance (C rCL) < 20 mL/min  using the formula of Cockcroft and Gault. 
b. Aspartate transaminase (AST) or alanine transaminase (ALT) > 5 x upper limit of 
normal (ULN) 
5. Hyponatremia defined as sodium < 13 0 mEq/L  
6. Unable to take oral medication when inform ed consent is obtained.  
7. Patients with a legal guardian or who are incarcerated.   
8. Treatment with strong CYP3A inhibitors or inducers. A list of strong CYP3A inhibitors 
and inducers is provided in Appendix 3. 
9. Pregnant and breastfeeding women . 
4.3. Screen Failures 
Screen failures are defined as patient s who consent to participate in the clinical study but are not 
subsequently randomized for treatment in the study. Minimal information is required for these 
patients includ ing demographics, screen failure details, eligibility criteria, and any serious 
adve rse event  (SAE)  not related to C OVID-19. 
Individuals who do not meet the criteria for participation in this study (screen failure) may be 
rescreened. Rescreened patient s should be assigned the same patient number as for the initial 
screening.  
4.4. Randomization /Stratification  
Randomization will be performed prior to dosing. 
Randomization will be stratified based on the following stratification factors and will maintain 
the 2:1 allocation between treatment arms (selinexor vs placebo) within each of the stratification categories:  
• Use of concomitant therapi[INVESTIGATOR_014]: an anti -viral (e.g., remdesivir ) or an anti- inflammatory 
(e.g. hydroxychloroquine, biologics targeting e.g., IL -6 or IL-1).   
Clinical Study Protocol: XPORT -CoV -1001               Selinexor  
Version 6.0                                                                                                                                                08 May 2020 
Confidential   Page 38 of 74 Note: acetaminophen and nonsteroidal anti- inflammatory drugs (NSAIDs) will not 
constitute anti-inflammatory agents for the purposes of stratification.  
• High Risk Comorbidities: Age > 75, BMI> 30, cancer patients on chemotherapy, 
patients with cardiac (CAD, AMI, CHF) or pulmonary (COPD, emphysema) disease,  diabetes, hypertension. Stratification will be based on number of high risk 
como rbidities: (1  vs  ≥2  vs  0)  
Clinical Study Protocol: XPORT -CoV -1001               Selinexor  
Version 6.0                                                                                                                                                08 May 2020 
Confidential   Page 39 of 74 5. STUDY TREATMENT 
5.1. Study Treatment  Administered  
Table  3:  Study Treatment Administered  
Treatment  Name  [CONTACT_178215] ( XPOVIO®, KPT -330) / Placebo  
Type  Drug  
Dose Formulation  Tablet  
Unit Dose Strength  20 mg  
Dosage Level  20 mg, single dose  
Route of Administration  Oral 
A dose of 20 mg selinexor or matching placebo will be administered orally on Days 1, 3, and 5 
of each week for up to 2 weeks. If the patient is tolerating therapy and clinically benefitting 
(defined below), dosing can continue for an additional 2 weeks (on Days 15, 17, 19, 22, 24, and 
26). 
5.2. Dosing and Administration of Sel inexor /Placebo  
5.2.1. Labeling  
Medication labels for each blister pack of selinexor and matching placebo tablets will be in the 
local language and comply with the legal requirements of each country. They will include storage conditions for the drug and the kit identification number, with a space to record the 
patient ID number after the IMP is assigned.  
5.2.2. Dispensing Directions 
The Investigator or responsible site personnel must instruct the patient or caregiver to take the study treatment as per protocol. Study treatment will be dispensed to the patient by [CONTACT_178199]. Additional d ispensing instructions will b e provided in the Pharmacy Manual . 
5.2.3. Dosing Information 
Study treatment tablets should be taken orally with at least 120 mL (4 ounces) of water. Study treatment can  be taken with or without food. In order to avoid contact [CONTACT_37381], tablets must be 
swallowed  whole and should not be crushed. 
Eligible patients must be able to take oral medication when inform ed consent is obtained. If a 
patient is later intubated or unable to take oral medication during treatment, it is permissible to 
use selinexor suspension pr epared as below:  
A suspension of selinexor and/or placebo can be prepared by [CONTACT_178200], water, and the commercial suspension agent Ora-B lend
®.  The pharmacy should place 
one 20 mg active or placebo  tablet in a bottle (amber if available) and add 3 mL of water to 
disintegrate the tablet, then  add 9 mL of Orablend® suspending agent. Gentle swirling or 
Clinical Study Protocol: XPORT -CoV -1001               Selinexor  
Version 6.0                                                                                                                                                08 May 2020 
Confidential   Page 40 of 74 inversion of the capped bottle will mix the suspension and suspend selinexor for dosing.  The 
resulting suspension should be dosed within 4 hours.  Administer the suspension to the patients using an oral dosing syringe via a nasogastric (NG) or percutaneous endoscopic gastrostomy (PEG) feeding tube. Rinse the bottle, syringe and tube with  40 mL  to 110 mL of saline and dose 
the sali ne rinse to the patient to ensure complete delivery of the selinexor/placebo dose. 
Handling Precaution:  Selinexor tablets are coated for easy handling. Do not break, cut, or crush selinexor tablets because of increased risk of dermatologic toxicity (e.g. , rash) from exposure to 
the active ingredient in the tablets.  
Handling Precaution: The tablets quickly disintegrate in water (<10 min) without being crushed. Please wear gloves when handling the suspension to prevent unintended exposure to the active ingredient.  The site pharmacy should consult the pharmacy manual for full instructions on 
preparing and handling the suspension and for alternative suspending agents should Ora- Blend
® 
be unavailable. 
5.3. Missed or Vomited Doses of Selinexor  
5.3.1. Missed Doses of Sel inexor 
Missed selinexor doses should be managed as follows: 
• If a dose was missed, the dose should be taken the next day.  Subsequent doses must 
respect the required  48 hour interval planned schedule. All missed and delayed doses 
should be documented 
• If a d ose must be skipped (e.g., due to recommendation of treating physician), the 
next dose will be taken as per schedule. All missed and delayed doses should be 
documented. 
5.3.2. Vomited Doses of Selinexor 
If a dose is vomited ≤[ADDRESS_209321] t ablet is seen, it will be replaced. If 
vomiting occurs more than 1 hour after dosing, it will be considered a complete dose. 
5.4. Preparation/Handling/Storage/Accountability  
• The Investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study treatment received and any discrepancies 
are reported and resolved before use of the study treatment. 
• Only patients randomized in the study may receive study treatment and only 
authorized site staff may supply or administer study treatment. All study  treatment 
must be stored in a secure, environmentally controlled, and monitored (manual or automated) area in accordance with the labeled storage conditions with access limi ted 
to the I nvestigator and authorized site staff.  
• The Investigator, institution, or the head of the medical institution (where applicable) is responsible for study treatment accountability, reconciliation, and record maintenance ( i.e., receipt, reconciliation, and final disposition records). 
Clinical Study Protocol: XPORT -CoV -1001               Selinexor  
Version 6.0                                                                                                                                                08 May 2020 
Confidential   Page 41 of 74 • Further guidance and information for the final disposition of unused study treatment 
are provided in the Pharmacy Manual . 
5.5. Study Treatment  Compliance  
Administration of study treatment will be documented at each timepoint specified in the SoA. 
Deviation(s) from the prescribed dosage regimen should be recorded in the eCRF . 
5.6. Concomitant Medication  
5.6.1. Recommended Concomitant Treatments   
Provide prophyla ctic concomitant treatment with a [ADDRESS_209322] and/or other anti- emetic 
agents prior to and during treatment with selinexor. 
Ensure that patients are maintaining adequate fluid status and administer intravenous hydration 
as clinically warranted during the study treatment. 
5.6.2. Prohibited/Permitted  Concomitant Medications  
If in the  physician’s judgement, it is in the best interest of the patient to use anti -viral or anti-
inflammatory treatments, these treatments are to be documented in the patient’s chart and entered 
in the electronic case report form. Use of these treatments should  be carefully considered as they 
could potentially confound data interpretation. 
The use of strong CY P3A inhibitors or inducers while on selinexor treatment is not permitted .  
Selinexor should be interrupted during the use of these agents.  See Appendix [ADDRESS_209323] be documented, including the respective reason.   
The reason for dose modification should be directly related to a selinexor-associated AE, and not 
due to disease symptom/sign or to other medications.  
For all Grade ≥ 3 hematological or non- hematological AEs that are NOT seli nexor relate d, after 
consultation with the Medical Monitor and at the discretion of the Investigator, s elinexor dosing 
may be maintained. 
Selinexor should be discontinued for all selinexor- related  life-threatening (Grade 4) AEs.  
Table  4 summarizes the selin exor dose levels; Table  5 describes supportive care and dose 
adjustment guidelines. Deviations from the guidelines are permitted after discussion between the 
Sponsor and the treating physician. 
Table  4: Selinexor Dose Modification Steps for Adverse Reactions  
Recommended Starting Dosage First Reduction  
20 mg  
Days 1, 3 and 5 of each week  
(60 mg total per week) 20 mg  
Days 1 and 3 weekly (40 mg total per week) 
 
Clinical Study Protocol: XPORT -CoV -1001               Selinexor  
Version 6.0                                                                                                                                                08 May 2020 
Confidential   Page 42 of 74 Table 5: Selinexor Dosage Modification for Adverse Reactions  
Adverse Reactiona Occurrence  Action  
Hematologic Adverse Reactions  
Thrombocytopenia  
Platelet count 25,000 to 
less than 50,000/mcL  Any • Reduce selinexor by 1 dose level (see  Table  4). 
Platelet count 25,000 to 
less than 50,000/mcL with  
concurrent G3 bleeding Any • Interrupt selinexor  and provide appropriate supportive 
care.  
• Restart seli nexor after bleeding has resolved  at 1 dose 
level lower  (see Table  4). 
Platelet count less than 
25,000/mcL Any 
 • Interrupt selinexor  and provide appropriate supportive 
care.  
• Monitor until platelet count returns to at least 
50,000/mcL. 
• Restart selinexo r at 1 dose level lower  (see Table  4). 
Neutropenia  
Absolute neutrophil count 
of 0.5 to 1.0 x 109/L with  
fever  Any • Interrupt selinexor and provide provide  appropriate 
supportive care. 
• Monitor until neutrophil counts return to 1.0 x 109/L or 
higher. 
• Restart selinexor at 1 dose level  lower  (see Table  4). 
Absolute neutrophil count 
less than 0.5 x 109/L  Any • Interrupt selinexor and provide appropriate supportive 
care.  
• Monitor until neutrophil counts return to 1.0 x 109/L or 
higher. 
• Restart selinexor at 1 dose level lower  (see Table  4). 
Anemia  
Hemoglobin less than 8.0 
g/dL Any • Reduce selinexor by 1 dose level (see  Table  4). 
• Administer blood transfusions and/or other treatments 
per clinical guidelines.  
Life-threatening 
consequences Any • Interrupt selinexor and admini ster appropriate care  with 
blood transfusions and/or other treatments per clinical 
guidelines. 
• Monitor until patient stabilizes and hemoglobin is >8.0 g/dL. 
• Restart selinexor at 1 dose level lower (see Table  4). 
Non-Hematologic Adverse Reactions  
Hyponatremia  
Sodium level 130  mmol/L 
or less not due to disease 
or fluid status  Any • Interrupt selinexor  and provide appropriate supportive 
care.  
• Monitor until sodium levels return to 130 mmol/L or 
higher.  
Clinical Study Protocol: XPORT -CoV -1001               Selinexor  
Version 6.0                                                                                                                                                08 May 2020 
Confidential   Page 43 of 74 Adverse Reactiona Occurrence  Action  
• Restart selinexor  at 1 dose level lower (see Table  4). 
Nausea and Vomiting  
Grade 1 or 2 nau sea (oral 
intake decreased without 
significant weight loss, dehydration or malnutrition) OR Grade 1 or 2 vomiting 
(5 or fewer epi[INVESTIGATOR_165533]) Any • Maintain selinexor  and initiate additional anti-nausea 
medications.  
Grade 3 nausea 
(inadequate oral caloric or fluid intake)  OR Grade 3 or higher 
vomiting (6 or more epi[INVESTIGATOR_914]) Any • Interrupt selinexor .  
• Monitor until nausea or vomiting has resolved to Grade 
2 or lower or baseline.  
• Initiate additional anti -nausea m edications for Grade 2 
or lower.  
• Restart selinexor  at 1 dose level lower  (see Table  4) 
Diarrhea  
Grade 2 (increase of 4 to 6 
stools per day over 
baseline)  1st  • Maintain selinexor  and institute supportive care.  
 
 2nd and 
subsequent • Reduce selinexor  by 1 dose level (see  Table  4). 
• Institute  supportive care.  
Grade 3 or higher 
(increase of 7  stools or 
more per day over 
baseline; hospi[INVESTIGATOR_373])  Any 
 • Interrupt selinexor  and institute supportive care.  
• Monitor until diarrhea resolves to Grade 2 or lower.  
• Restart seli nexor at 1  dose level lower (see Table  4).  
Weight Loss and Anorexia  
Weight loss of 10% to less 
than 20%  
OR anorexia associated 
with significant weight 
loss or malnutrition  not 
due to intensive care status  Any • Interrupt selinexor  and institute supportive care.  
• Monitor until weight returns to more than 90% of baseline weight.  
• Restart seli nexor at 1  dose level lower (see  Table  4). 
Other Adverse Reactions  
Grade 3 or 4  non-
hematologic reactions Any • Interrupt selinexor . 
• Monitor until resolved to Grade 2 or lower, restart 
selinexor  at 1 dose level lower (see Table  4).  
Life-threatening 
hemato logical and non-
hemato logical ( Grade 4 ) 
AEs related  to selinexor  Any • Discontinue selinexor  
a National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Only 
adverse reactions to selinexor should lead to dose adjustments.  
Clinical Study Protocol: XPORT -CoV -1001               Selinexor  
Version 6.0                                                                                                                                                08 May 2020 
Confidential   Page 44 of 74 6. DISCONTINUATION OF STUDY TREATMENT AND PATIENT 
DISCONTINUATION/WITHDRAWAL  
6.1. Discontinuation of Study Treatment  
In rare instances, it may be necessary for a patient to permanently discontinue study treatment . If 
study treatment  is permanently discontinued, the patient  will remain in the study to be evaluated 
for overall mortality . See the S oA for data to be collecte d at the time of discontinuation of study 
treatment. 
Selinexor should be discontinued for all selinexor- related  life-threatening (Grade 4) AEs.  
6.2. Patient  Discontinuation/Withdrawal from the Study  
A patient may withdraw from the study at any time at his/her own request or may be withdrawn 
at any time at the discretion of the I nvestigator  for safety, behavioral, compliance, or 
administrative reasons. W aivers for eligibility criteria for enrollment will not be  permitted. The 
criteria given below are reasons the investigator must consider for removal of patients from 
study.  
The Investigator must determine the primary reason for a patient’s discontinuation of study 
treatment/withdrawal from the study and record this information on the e lectronic case report 
form ( eCRF ). 
The Investigator may remove a patient from study treatment for any of the following reasons: 
• Unacceptable AEs or toxicity that cannot be managed by [CONTACT_90994] 
• Significant deviations from inclusion/exclusion criteria  
• Missed / unscheduled / off -schedule / incomplete / incorrect assessments that result in 
patients being put at risk  
• Any other medically appropriate reason or significant protocol violation, in the opi[INVESTIGATOR_689]. 
The Investigator must remove a patient from study treatment for any of the following reasons: 
• Patient withdraws consent to continue study treatment.  
• Worsening clinical condition defined as at least 5 days of intubation/ECMO with no 
evidence of clinical impro vement.  Patients who are clinically stable based on oxygen 
requirements on mechanical ventilation will be permitted to remain on study. 
• Grade ≥3 nausea or vomiting despi[INVESTIGATOR_178155]. 
• Progression of renal dysfunction requiring dialysis. 
• Grade [ADDRESS_209324] to follow -up if he/she unable to be contact[CONTACT_9298]. 
Clinical Study Protocol: XPORT -CoV -[ADDRESS_209325] of the 
study. All study staff will be blinded to the treatment assignments and study drug will be 
administered in a blinded manner.  
Unblinding of treatment assignments should be undertaken for safety reasons when it is essential 
for effective treatment of the patient.  
Unblinding is performed using the IRT. When the investigator contacts the IRT to unblind a patient, he/she must provide the requested patient identifying information and confirm the necessity to unblind the patient. The Investigator will then receive details of the drug treatment 
for the specified patient.  
The entire study population will be unblinded at the end of the study and the unblinding information will be shared with each study site.  
6.5. Early Termination of the Study  
The study may be terminated at the sole discretion of the Sponsor for any reason, including 
medical or ethical reasons affecting the continued performance of the study, or difficulties in the recruitment of patients. If this occurs, the Sponsor will notify  independent ethics committees 
(IECs ), institutional review boards ( IRBs ), Investigators, and regulatory authorities.  
6.6. End of Study  
End of Study will occur when the last patient has completed the 30-day Safety follow up period 
(after their last dose of study treatment), has withdrawn consent or has died, whichever comes first.  
Clinical Study Protocol: XPORT -CoV -1001               Selinexor  
Version 6.0                                                                                                                                                08 May 2020 
Confidential   Page 46 of 74 7. STUDY ASSESSMENTS AND PROCEDURES  
• Study procedures and their timing are summarized in the SO A.  
• Immediate  safety concerns should be discussed with the Sponsor immediately upon 
occurrence or awareness to determine if the patient  should continue or discontinue 
study treatment . 
• Procedures conducted as part of the patient ’s routine clinical management (e.g., blood 
count) and obtained prior to  signing of the informed consent form ( ICF) may be 
utilized for screening or baseline purposes provided the procedures met the protocol-
specified criteria and were performed within the time frame defined in the S OA. 
• Please reference the Karyopharm Risk Management Plan for Conduct of Clinical 
Trials During the COVID -19 Pandemic as the document may address procedures 
being performed as a part of this clinical trial.  
7.1. Baseline Assessments  
7.1.1. Demographics 
Patient demographics (including date of birth, sex, ethnicity , and race ) will be collected.  
7.1.2. Medical History  
The medical history will include co-infections, baseline symptoms as well as active medical 
conditions. Data  from standard-of- care procedures will be part of the patient's medical history 
and may be used for study purposes. 
In addition, the smoking history of the patient will be recorded. 
7.1.3. Disease History  
The disease history will include collection of COVID -19 symptom onset date as well as date and 
time of admission to hospi[INVESTIGATOR_178163] (COVID-diagnosis/ COVID associated 
complication or Concomitant Illness).  
7.2. Efficacy Assessments  
Study procedures and their timing are summarized in the SOA. 7.3. Safety Assessments  
Planned time points for all safety assessments are provided in the S OA. 
7.3.1. Physical Examinations   
The physical examination will be performed according to the standards at each institution. 
Complete p hysical examination, including vital signs, will be performed in the screening  visit  
and if possible , at the End of Study visit. Suspected selinexor associated s ymptom- directed 
physical exam should be performed at any time directed by [CONTACT_178201].   
Clinical Study Protocol: XPORT -CoV -1001               Selinexor  
Version 6.0                                                                                                                                                08 May 2020 
Confidential   Page 47 of 74 Vital signs will include:  
• Body temperature (°C or °F)  
• Systolic and diastolic blood pressure and pulse rate  
• Respi[INVESTIGATOR_13581]  
• Oxygen Saturation 
− If patient requires respi[INVESTIGATOR_72789], then type of assistance, start and end date 
as well as reason for removal of mechanical ventilation will be documented in the 
eCRF.  
Clinically relevant findings made after the start of study treatment, which meet the definition of 
an AE, must be recorded on the AE eCRF. 
7.3.2. Ordinal Score  
The Ordinal score is a composite measure of clinical improvement and/or survival, assessed on a 
daily basis.  
The severity rating is on a 8-point ordinal scale: 
1. Death ; 
2. Hospi[INVESTIGATOR_057], on invasive mechanical ventilation or extracorporeal membrane 
oxygenation (ECMO);  
3. Hospi[INVESTIGATOR_057], on non-invasive ventilation or high flow oxygen devices;  
4. Hospi[INVESTIGATOR_057], requiring supplemental oxygen;  
5. Hospi[INVESTIGATOR_36515], not requiring supplemental oxygen - requiring ongoing medical care 
(COVID- 19 related or otherwise);  
6. Hospi[INVESTIGATOR_057], not requiring supplemental oxygen - no longer requires ongoing medical 
care;  
7. Not hospi[INVESTIGATOR_057], limitation on activities and/or requiring  home oxygen;  
8. Not hospi[INVESTIGATOR_057], no limitations on activities.  
7.3.3. Electrocardiograms  
Standard 12- lead ECGs will be performed at the time points specified in the S oA.  
The Investigator will interpret the ECG using 1 of the following categories: normal, abnormal 
but not clinically significant, or abnormal and clinically significant.  
The time the ECG was performed, and the following parameters will be recorded in the eCRF: 
heart rate, PR interval, QT interval, QRS interval, and QT corrected using either Bazett’s  or 
Fredericia’s formula.  
Clinical Study Protocol: XPORT -CoV -1001               Selinexor  
Version 6.0                                                                                                                                                08 May 2020 
Confidential   Page 48 of 74 7.3.4. Clinical Safety Laboratory Assessments  
Clinical laboratory tests (detailed in  Table 6 ) will be performed by [CONTACT_30107]’ local laboratories. In 
addition, laboratory tests will be collected and analyzed at times specified on the S oA. More 
frequent assessments may be performed if clinically indicated . 
Table  6: Clinical Safety Laboratory Tests 
Hematology  
Hem oglobin Leukocytes  (with differential)  Neutrophils  
Hematocrit  Platelet count Monocytes  
Basophils  Lymphocytes  Eosinophils  
Serum Chemistry  
Sodium  Creatinine  ALT  
Potassium  Glucose  AST  
Albumin  Calcium  Alkaline phosphatase 
Bicarbonate  Phosphate  Total bilirubin 
BUN/Urea  LDH  Total protein  
Coagulation  
PT aPTT INR 
Blood samples will be analyzed at each study center by a certified laboratory. The Investigator or 
designee will review the laboratory report after receipt of the results and assess the clinical significance of
 all abnormal values. Results should be reviewed prior to d osing and appropriate 
action taken for any clinically significant abnormal values.  
At any time during the study, abnormal laboratory values which are clinically relevant (e.g., require dose modification and/or interruption of study treatment, lead to clinical symptoms or signs or require therapeutic intervention), must be documented in the eCRF.  
If any abnormal laboratory value or test result constitutes a selinexor related AE, then these must 
be recorded on the AE eCRF. Values will be documented on the l aboratory report until 
stabilized, or the laboratory value returns to a clinically acceptable range (regardless of relationship to study treatment) or baseline. Any laboratory value that remains abnormal at the End of Study visit that is considered  clinica lly significant will be followed according to accepted 
medical standards for up to [ADDRESS_209326] u d y Pr ot oc ol: X P O R T -C o V -[ADDRESS_209327] u g  (see Secti o n 6). 
7. 3. 5. 1.  Pre g n a nc y Testi n g  
Pre g na nc y testi n g will be perf or me d o nl y f or fe males of c hil d beari n g p ote ntial. A ne gati ve ser u m 
h C G pre g na nc y test m ust be o btai ne d at Scree ni n g ( wit hi n [ADDRESS_209328] u d y treat me nt 
a d mi nistrati o n) a n d at t he e n d of treat me nt. Pre g na nc y testi n g ma y be perf or me d if cli nicall y 
i n dicate d d uri n g t he st u d y. 
7. 4.  P h ar m ac o ki netic Assess me nts  
P har mac o ki netic ( P K)  assess me nt will be perf or me d o n a s u bset of patie nts. Bl o o d dra ws f or P K 
a nal ysis of a p pr o xi matel y 2. 0 m L will be c ollecte d  f or t he meas ure me nt of plas ma 
c o nce ntrati o ns of seli ne x or  at 4 ± 1 hr, 2 4 ± [ADDRESS_209329] ual date a n d ti me ( 2 4- h o ur cl oc k ti me) of eac h sa m ple a n d seli ne x or 
d ose will be  rec or de d.  
If a patie nt e x perie nces e mesis wit hi n  t he first h o u r of seli ne x or d osi n g, n o P K sa m ples will be 
c ollecte d  f o r t hat d ose.  
Plas ma P K sa m ples will be s hi p pe d t o a bi oa nal ytical la b orat or y f or a nal ysis. Details f or 
c ollecti o n a n d pr ocessi n g of P K sa m ples ca n be f o u n d i n t he La b orat or y Ma n ual. Plas ma 
sa m ples w ill be a nal yze d via a vali date d hi g h- perf or ma nce li q ui d c hr o mat o gra p h y/ta n de m mass 
s pectr o metr y ( H P L C/ M S - M S) met h o d f or plas ma seli ne x or. 
7. 5.  C yt o ki ne Asses sme nts  
Bl o o d dra ws f or c yt o ki ne a nal ysis of a p pr o xi matel y 2. [ADDRESS_209330] ora ge a n d deli ver y of t he sa m ples will be 
i ncl u de d i n t he Cli nical Pr ot oc ol La b ma n ual. 
7. 7.  Vir al  Assess me nts  
C CI 
Clinical Study Protocol: XPORT -CoV -1001               Selinexor  
Version 6.0                                                                                                                                                08 May 2020 
Confidential   Page 50 of 74 8. ADVERSE EVENTS  
8.1. Information on Reporting Adverse Events  
8.1.1. Definitions  
• Adverse event (AE) : Any untoward medical occurrence in a patient or clinical 
investigation subject administered a pharmaceutical product and which does not 
necessarily have to have a causal relationship with this treatment. An AE can 
therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of 
study treatment, whether or not considered related to the study treatment.  
• Life-threatening adverse event or life- threatening suspected adverse reaction : An 
adverse event or suspected adverse reaction is considered "life-threatening" if, in the view of either the investigator or sponsor, its occurrence places the patient or subject 
at immediate risk of death. It does not include an adverse event or suspected adverse reaction that, had it occurred in a more severe form, might have caused death. 
• Treatment -emergent adverse event (TEAE) : Any event that was not present prior to 
the initiation of study treatment or any event already present that worsens in either 
intensity or frequency following exposure to study treatment.  
• Serious adverse event (SAE):  Any untoward medical occurrence that , at any dose, 
results in death; is life threatening (ie, an event in which the patient was at risk of death at the time of the event; it does not refer to an event that hypothetically might have caused death if it were more severe); requires inpatient hospi[INVESTIGATOR_1081]; results in persistent or significant disability/incapacity; or is a congenital anomaly/birth defect. Important medical events that may not result in death, be life- threatening, or require hospi[INVESTIGATOR_178164], based upon appropriate medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse. (See Section  [IP_ADDRESS] for additional information about SAE reporting.)  
• Suspected adverse reaction : Any adverse event for which there is a reasonable 
possibility that the drug caused the adverse event. For the purposes of IND safety 
reporting, "reasonable possibility" means there is evidence to suggest a causal 
relationship between the drug and the adverse event. Suspected adverse reaction implie s a lesser degree of certainty about causality than adverse reaction, which 
means any adverse event caused by a drug.  
• Unexpected adverse event or unexpected suspected adverse reaction : An adverse 
event or suspected adverse reaction is considered "unexpecte d" if it is not listed in the 
investigator brochure or is not listed at the specificity or severity that has been observed; or, if an investigator brochure is not required or available, is not consistent 
Clinical Study Protocol: XPORT -CoV -1001               Selinexor  
Version 6.0                                                                                                                                                08 May 2020 
Confidential   Page 51 of 74 with the risk information described in the general investigational plan or elsewhere in 
the current application, as amended. For example, under this definition, hepatic 
necrosis would be unexpected (by [CONTACT_14213]) if the investigator 
brochure referred only to elevated hepatic enzymes or hepa titis. Similarly, cerebral 
thromboembolism and cerebral vasculitis would be unexpected (by [CONTACT_36093]) if the investigator brochure listed only cerebral vascular accidents. 
"Unexpected," as used in this definition, also refers to adverse events or suspected adverse reactions that are mentioned in the investigator brochure as occurring with a 
class of drugs or as anticipated from the pharmacological properties of the drug, but 
are not but are not specifically mentioned as occurring with the particular drug under investigation. 
8.1.2. Recording of Adverse Events 
All AEs that begin or worsen after the patient has provided informed consent will be recorded. 
Those AEs that occur prior to study dosing, can be  captured in the patient’s baseline conditions, 
however if any of these AEs are considered, serious, these are to be reported both to Pharmacovigilance and documented in the eCRF AE log. For events that are considered by [CONTACT_178202], the monitoring of the AE should be continued through the end of the study, for at least [ADDRESS_209331] dose of study drug (if the end of 
the study is within [ADDRESS_209332] dose of study drug), or until the AE has resolved.  
Investigators should use medical judgment in determining whether a particular symptom or sign is considered to be a part of COVID-19 infection clinical course or not and report them or not as AEs according to such determination. When a clear determination cann ot be made by [CONTACT_4520], a sign or symptom should be reported as AEs. All deaths irrespective of cause of death including due to COVID-19 during the study should be reported to the Sponsor using an SAE form . 
Adverse events (including laboratory abn ormalities that constitute AEs) should be described 
using a diagnosis whenever possible, rather than individual underlying signs and symptoms. When a clear diagnosis cannot be identified, each sign or symptom should be recorded as a separate AE.  
The Investigator should ask the patient non-leading questions to determine if any AEs have occur red during the study, since the last study visit. Adverse events  may also be recorded when 
they are volunteered by [CONTACT_102], or through physical examination, laboratory tests, or other clinical assessments.  
An AE should be followed until its resolution or until it is judged to be permanent, and assessment should be made at each visit (or more frequently, if necessary) of any changes in severity of the event, the suspected relationship to the study treatment, the interventions required to treat the event, and the outcome. 
[IP_ADDRESS]. Laboratory Test Abnormalities 
Laboratory abnormalities that constitute an AE in their own right (i.e. , are considered to be 
clinically significant, indu ce clinical signs or symptoms, require concomitant therapy, or require 
changes in study treatment), should be recorded on the Adverse Events eCRF. Whenever 
Clinical Study Protocol: XPORT -CoV -1001               Selinexor  
Version 6.0                                                                                                                                                08 May 2020 
Confidential   Page 52 of 74 possible, a diagnosis, rather than a symptom should be provided (e.g., anemia instead of low 
hemoglobin).  
Laboratory abnormalities that meet the criteria for an AE should be followed until they have 
returned to b aseline levels (as measured during the S creening  visit) or an adequate explanation of 
the abnormality is identified. When an abnormal laboratory or test result corresponds to a 
sign/symptom of an already reported AE, it is not necessary to separately record the 
laboratory/test result as an additional event.  
A laboratory abnormality that does not meet the definition of an AE should not be reported as an 
AE. A Grade 3 or 4 event (considered to be severe per NCI CTCAE , v. 5.0) does not 
automatically indicate an SAE unless it meets the definition of serious as defined in Section  8.1 
and/or as per the opi[INVESTIGATOR_689]. A laboratory abnormality that results in a dose being held or modified would, by [CONTACT_108], be an AE and must be recorded as such in the 
eCRF. 
[IP_ADDRESS]. Adverse Event Severity  
The term “severe” is used to describe the intensity of an AE; the event itself could be of 
relatively minor clinical significance (e.g., ‘severe’ headache). This is not the same as a “serious” 
AE. 
The severity of the AE will be g raded by [CONTACT_178203], v. 5.0 (the NCI CTCAE files can be accessed online at the following URL: http://evs.nci.nih.gov/ftp1/CTCAE/About.html ).  
If there is not a specific NCI CTCAE grading scale for an AE, the severity will be characterized 
as mild, moderate,  severe, or life -threatening , according to the following definitions:  
• Grade 1 (m ild) events are usually transient in nature and do not interfere with the 
patient’s daily activities.  
• Grade 2 (moderate) events introduce a low level of inconvenience or concern to the patient and may interfere with daily activities.  
• Grade 3 (s evere) events interrupt the patient’s usual daily activities.  
• Grade 4 events are those that are considered to be l ife-threatening.  
8.1.3. Adverse Event Causality  
The Investigator will make a judgment regarding the relationship of the AE to study treatment, as defined below. 
• Not related: These events will lack a strong temporal relationship of the event to the 
study treatment, making a causal relationship not reasonably possible.  Exposure to other drugs, therapeutic interventions, or underlying conditions may provide a 
sufficient explanation  for the event. 
• Related:  Ther e is a temporal relationship of the event to the study treatment making a 
definitive relationship, and the event is more likely explained by [CONTACT_159457], therapeutic interventions, or underlying 
conditions. 
Clinical Study Protocol: XPORT -CoV -[ADDRESS_209333] 
be reported (in addition to SAEs that occur after the first dose of study treatment). 
[IP_ADDRESS]. Events that Do Not Meet the Definition of a Serious Adverse Event  
Patients are hospi[INVESTIGATOR_178165]. If patients are kept in hospi[INVESTIGATOR_174159] a social reason 
or an administrative reason after they are considered to be discharged, these events will no t be 
considered an SAE. Any other e lective hospi[INVESTIGATOR_178166]. Death due to 
COVID-19 should be reported to the Karyopharm PV department using a SAE form.  
[IP_ADDRESS]. Recording of Serious Adverse Events  
It is the responsibility of the Investigator to record and document all SAEs occurring from the 
time when the ICF is signed until at least [ADDRESS_209334] be r eported on the designated Sponsor ’s SAE Report Form in addition to being 
recorded in the eCRF. The original SAE report form must be retained in the Investigator’s site 
file. 
All applicable sections of the SAE Report Form must be completed in order to provi de a 
clinically thorough report. The Investigator must assess and record the relationship of each SAE to study treatment and complete the form  in English. 
See ICH E2A (Clinical Safety Data Management: Definitions and Standards for Expedited Reporting, Atta chment 1) for key data elements that are required for expedited reporting. 
[IP_ADDRESS]. Reporting of Serious Adverse Events 
Every SAE, regardless of the causal relationship to the study treatment, occurring after the 
patient has signed informed consent, until at least [ADDRESS_209335] be immediately emailed or faxed to: 
Pharmacovigilance Department  
Karyopharm Therapeutics Inc. 
Email: [EMAIL_633] 
Fax: +[PHONE_3530] ([LOCATION_003]) 
[PHONE_3846] ([LOCATION_013]) 
Any SAE observed after the 30-day follow-up period should only be reported to Karyopharm if 
the Investigator suspects that the SAE has a causal relationship to the study treatment. Recurrent 
epi[INVESTIGATOR_1841], complications, or progression of the initial SAE must be reported, as follow-up to the original epi[INVESTIGATOR_1865] , within 24 hours of the Investigator receiving the follow-up information.  
Clinical Study Protocol: XPORT -CoV -1001               Selinexor  
Version 6.0                                                                                                                                                08 May 2020 
Confidential   Page 54 of 74 An SAE should be followed until its resolutio n or until it is judged to be permanent . An 
assessment should be made at each study visit (or more frequently, if necessary) of any changes 
in severity of the event, the suspected relationship to the study treatment, the interventions 
required to treat the  event, and the outcome of the event. 
[IP_ADDRESS]. Suspected Unexpected Serious Adverse Reactions 
Suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) are SAEs that are unexpected and 
judged by [CONTACT_37391]. All 
S[LOCATION_003]Rs will be collected and reported to the competent authorities and relevant ethics committees in accordance with the FDA’s “Safety Reporting Requirements for Investigational 
New Drugs and Bioanalytical/Bioequivalence Studies” or as per national regulatory requirements 
in participating countries. 
If required by [CONTACT_427], the Investigator is responsible for notifying his/her IRB or local 
ethics committee of all SAEs.  
8.3. Procedures for Handling Special Situations  
8.3.1. Pregnancy and Breastfeeding  
Note: Pregnancy per se is not considered to be an AE; however, it is discussed here because of 
the importance of reporting pregnancies that occur during studies and because a medical occurrence observed in the mother or fetus/newborn would be classifi ed as an AE.  
Female patients of childbearing potential and fertile male patients will be informed as to the potential risk of conception while participating in this study and will be advised that they must use highly effective contraception listed below ( i.e., results in a low failure rate when used 
consistently and correctly) during the dosing period and for a period of at least 3 months after the end of treatment. 
Highly effective methods include: 
• Combined (estrogen and progestogen containing) hormonal c ontraception associated 
with inhibition of ovulation: 
− Oral 
− Intravaginal  
− Transdermal  
• Progestogen-only hormonal contraception associated with inhibition of ovulation: − Oral 
− Injectable  
− Implantable  
• Intrauterine device  
• Intrauterine hormone -releasing system  
• Bilateral tubal occlusion  
Clinical Study Protocol: XPORT -CoV -1001               Selinexor  
Version 6.0                                                                                                                                                08 May 2020 
Confidential   Page 55 of 74 • Vasectomized partner  
• Sexual abstinence 
If a patient is confirmed pregnant during the study, study drug administration must be 
discontinued immediately. The Investigator must immediately notify the Sponsor’s Medical Monitor of the event and record the pregnancy on the Pregnancy Form (provided by [CONTACT_159430]). The initial information regarding a pregnancy must be forwarded to Karyopharm’s Pharmacovigilance by [CONTACT_37392] [ADDRESS_209336] knowledge of its occurrence.  
The pregnancy should be followed up to determine the outcome, including any spontaneous or 
voluntary termination, details of the birth, and any birth defects, congenital abnormalities, or maternal and/or newborn complications.  
All pregnancies occurring within 3 months after the patient’s last dose of study drug must be 
reported to Karyopharm, regardless of whether the patient received selinexor or other study drugs, withdraws from the study, or the study is completed. Patients should be instructed to inform the Investi gator regarding any pregnancies.  
Any SAE that occurs during pregnancy must be recorded on the SAE report form (e.g. maternal serious complications, therapeutic abortion, ectopic pregnancy, stillbirth, neonatal death, congenital anomaly, or birth defect) and reported within 24 hours in accordance with the procedure for reporting SAEs (described in Section  [IP_ADDRESS] ).  
A pregnancy in a female partner of a male patient must be reported to Karyopharm within [ADDRESS_209337] milk. Mothers should not breastfeed while being treated with selinexor-containing regimen. 
8.3.2. Abuse, Misuse, Medication Errors and Overdose 
All incidences of abuse, misuse, medication errors and overdose are to be reported to 
Karyopharm Pharmacovigilance on an SAE report form to  pharmacovigilance 
@karyopharm.com, regardless of whether or not there is an associated AE or SAE.  
[IP_ADDRESS]. Overdose  
An overdose is a deliberate or accidental administration of any study treatment to a study patient, at a dose greater than that which was assigned to that patient per the study protocol. If an 
overdose occurs, the Investigator and Karyopharm should be notified immediately, and the patient should be observed closely for AEs. Resulting symptoms should be treated, as 
appropriate, and the incident of overdose and related AEs and/or treatment should be 
documented in the patient’s medical record and in the eCRF. Information regarding the o verdose 
is to be recorded  on an SAE report form and sent to Karyopharm Pharmacovigilance, regardless 
of whether or not an AE or SAE has occurred due to the overdose. If the overdose is associated with an SAE, the SAE report form must be submitted to Karyopharm Pharmacovigilance within [ADDRESS_209338] be submitted as soon as 
possible. 
Clinical Study Protocol: XPORT -CoV -1001               Selinexor  
Version 6.0                                                                                                                                                08 May 2020 
Confidential   Page 56 of 74 Doses of selinexor of up to 160 mg per week (80 mg twice weekly, the approved dose in 
RRMM ) and weekly doses of up to [ADDRESS_209339] been given to patients with advanced cancers 
with adequate tolerability .  No specific antidotes for overdose are known at this time.  
[IP_ADDRESS]. Abuse, Misuse, or Medication Error 
Abuse is the persistent or sporadic, intentional excessive use of the study treatment which is accompanied by [CONTACT_3584].  
A medication error is any preventable incident that may cause or lead to inappropriate study 
treatment use or patient harm while the study treatment is in the control of the health care professionals or patients. Such incident may be due to health care professional practice, product 
labeling, packaging and preparation, procedures for administration, and systems, including the 
following: prescribing, order communication, nomenclature, compounding, dispensing, distribution, administration, education, monitoring, and use. 
All occurrences of abuse, misuse, or medication error with any study treatment are to be 
recorded  on an SAE report form and sent to Karyopharm Pharmacovigilance, regardless of 
whether or not an AE or SAE has occurred due to the abuse, misuse, or medication error. If the 
abuse, misuse, or medication error is associated with an SAE, the SAE report form must be 
submitted to Karyopharm Pharmacovigilance within [ADDRESS_209340] u d y Pr ot oc ol: X P O R T -C o V -1 0 0 1                     Seli ne x or  
Versi o n 6. 0                                                                                                                                                 0 8 Ma y 2 0 2 0  
C o nfi de ntial   Pa ge 5 7  of 7 4  9.  S T A TI S TI C A L C O N SI D E R A TI O N S  
A statistical a nal ysis pla n ( S A P) will be fi nalize d pri or t o data base l oc k. A n y c ha n ges fr o m t he 
statistical a nal yses descri be d i n t his d oc u me nt will be descri be d i n t he S A P, a n d a n y de viati o n 
fr o m t he fi nal S A P will be descri be d i n t he fi nal re p ort.  
9. 1.  Ge ner al C o nsi der ati o ns  
Ta b ulati o ns will be pr o d uce d f or a p pr o priate de m o gra p hic, baseli ne, efficac y, a n d safet y 
para meters.  
F or cate g orical varia bles, s u m mar y ta b ulati o ns of t he n u m ber a n d perce nta ge of patie nts wit hi n 
eac h cate g or y ( wit h a cate g or y f or missi n g data) of t he para meter will be prese nte d.  
F or c o nti n u o us varia bles, t he n u m ber of patie nts, mea n, me dia n, sta n dar d de viati o n, mi ni m u m, 
a n d ma xi m u m val ues will be prese nte d. 
9. 1. 1.  Pr oce d ures f or H a n dli n g Missi n g D at a  
F or A Es, missi n g dates will n ot be i m p ute d; h o we ver, if partial dates are a vaila ble, t he y will be 
use d t o assess if t he  A E occ urre d d uri n g t he treat me nt peri o d. Missi n g se verities of A Es will n ot 
be i m p ute d a n d will be c o nsi dere d missi n g i n a n y ta b ulati o ns of A E se verit y. If a n A E is missi n g 
a res p o nse t o t he q uesti o n re gar di n g relati o ns hi p t o treat me nt, t he e ve nt will be c o nsi dere d t o be 
relate d.  
9. 2.  S a m ple Size Deter mi n ati o n  
A p pr o xi matel y 2 4 7 patie nts  
 
9. 3.  P o p ul ati o ns f or A n al yses 
T he i nte nt- t o -treat (I T T) p o p ulati o n will c o nsist of all patie nts w h o are ra n d o mize d i n t he st u d y  
wit h c o nfir me d S A R S- C o V [ADDRESS_209341] u d y treat me nt.  
T he all -treat ( A T) p o p ulati o n will c o nsist of all patie nts w h o t o o k at least o ne d ose of st u d y 
treat me nt o n t his st u d y  a n d ha ve c o nfir me d S A R S- C o V [ADDRESS_209342] atistic al A n al yses  
S u m mar y ta b ulati o ns will be pr o vi de d f or dis p ositi o n, de m o gra p hic, baseli ne, efficac y, a n d 
safet y data as n ote d i n t he f oll o wi n g secti o ns.  
T his secti o n is a s u m mar y of t he pla n ne d statistical a nal yses of t he pri mar y a n d sec o n dar y 
e n d p oi nts. 
9. 4. 1.  Effic ac y A n al yses 
Efficac y a nal yses will be perf or me d i n I T T p o p ulati o n. If t he pri mar y e n d p oi nt, ( Da y 1 4 O SI) , is 
si g nifica nt, t he 4 ke y sec o n dar y e n d p oi nts will be se q ue ntiall y teste d i n t he or der liste d bel o w. If C CI 
Clinical Study Protocol: XPORT -CoV -1001               Selinexor  
Version 6.0                                                                                                                                                08 May 2020 
Confidential   Page 58 of 74 any null hypothesis is not rejected in this sequence of te sts, formal sequential testing will be 
stopped and the analyses of any endpoints thereafter will be nominal only.   
• Time to recovery defined as improvement from baseline score of 3 to ≥4 or from a 
baseline score of 4 to ≥5  
• Proportion of patients with at  least a 2 point improvement (increase) in the Ordinal Scale  
from baseline to Day 7.  
• Proportion of patients with at least a 1 point improvement (increase) in the Ordinal Scale 
from baseline to Day 7  
• Proportion of patients with at least a 1 point improvement (increase) in the Ordinal Scale 
from baseline to Day 14. 
• Time to an improvement of 2 point using WHO Ordinal Scale Improvement (TTCI- 2) 
• Time to clinical improvement (TTCI -1): defined as the time from randomization to an 
improvement of 1 point on the Ordinal Scale  
• Overall Death rate  on Day 28 (DR)  
• Rate of mechanical ventilation (RMV) 
The difference in binary endpoints between treatment arms will be calculated with a 95% 
confidence interval (CI). Comparison of the these  endpoints between the 2 treatment arms will 
be performed using the Cochran- Mantel -Haenszel (CMH) test stratified by [CONTACT_178204]. The CMH estimate of the odds ratio and its 95% CI and the p-value for testing the treatment difference will be reported.  
The analy sis of time to event endpoints will be performed by [CONTACT_178205] a log -rank 
test. The median will be estimated with a 95% CI for each treatment arm using the Kaplan- Meier 
method. Hazard ratios with the associated 95% CI will be estimated by a str atified Cox 
proportional hazards model, using Efron’s method of tie handling, with treatment as the factor. 
The strata will be the same stratification factors used for randomization.  
Analyses of all other secondary endpoints will be nominal only. D etails w ill be specified in the 
SAP.  
9.4.2. Safety Analyses 
Safety analyses will be based on the reported AEs and other  clinical information. 
Safety analyses will be performed in AT population.  
The safety and tolerability of seli nexor will be evaluated by [CONTACT_178206]- related AE reports, 
physical examinations, and laboratory safety evaluations. The grading of the severity of the AEs 
will be done according to CTCAE, v.5.0. Investigators will provide their assessment as either the 
AE is related or not related to study drug.  
Treatment -emergent AEs, SAEs, AEs of at least Grade [ADDRESS_209343] dose . Related AEs will be those with an Investigator 
determination of related to study drug.  
Clinical Study Protocol: XPORT -CoV -1001               Selinexor  
Version 6.0                                                                                                                                                08 May 2020 
Confidential   Page 59 of 74 9.4.3. Pharmacok inetic Analysis 
Plasma samples will be analyzed via a validated HPLC/MS -MS method for plasma selinexor 
concentration. Selinexor C max and C trough data will be summarized . Selinexor concentration data 
might also  be analyzed using a population PK modeling approach if deemed necessary. Details 
of the population PK analysis, including software, post- processing and statistical analysis, will 
be outlined in a separate Data Analysis Plan to be completed prior to database lock. 
9.4.4. Pharmacodynamic Analysis 
Plasma proteins will be assessed and quantified by [CONTACT_178207] a central lab . 
9.4.5. Viral Analysis  
Viral testing  will be assessed and quantified. 
9.5. Criteria for Stoppi[INVESTIGATOR_178167]:   
A. If the overall number of patients enrolled is ≤[ADDRESS_209344] ( DSMB) meeting: 
1. The absolute difference in the death rate in the treatment arm  versus the control arm  is 
>30%  
2. The absolute difference in the need for invasive ventilation in the treatment arm versus 
the control arm is >30%  
3. The absolute difference in the rate of Grade 3 or 4 nausea or vomiting in the treatment 
arm versus the control arm is >20%  
B. If the overall number of patients enrolled is >60 patients , the study will be halted if any 1 of 
the following conditions are met at an IA or DSMB meeting: 
1. The absolute difference in the death rate in the treatment arm versus the control arm is 
>20%  
2. The absolute difference in the need for invasive ventilation in the treatment arm versus 
the control arm is >20%  
3. The absolute difference in the rate of Grade 3 or 4 nausea or vomiting in the treatment 
arm versus the control arm is >20%  
C. If the overall number of patients enrolled is >120 patients , the study will be halted if any 1 of 
the following conditions are met at an IA or DSMB meeting: 
1. The absolute difference in the death rate in the treatment arm versus the control arm is 
>10%  
2. The absolute difference in the need for invasive ventilation in the treatment arm versus 
the control arm is > 10% 
Clinical Study Protocol: XPORT -CoV -1001               Selinexor  
Version 6.0                                                                                                                                                08 May 2020 
Confidential   Page 60 of 74 3. The absolute difference in the rate of Grade 3 or 4 nausea or vomiting in the treatment 
arm versus the control arm is >10%  
In addition, each IA includes a futility analysis which will determine if there is no significant improvement in the ordinal score in the treatment arm compared with the control arm.  
9.6. Interim Analyses  
The first IA  occurs 14 days after approximately 74 patients are randomized . This IA is for futility 
only. The futility boundary p- value will be calculated using the Lan DeMets spending function 
with the O’Brien -Fleming type of boundary based on the actual number of patients who have 
completed 14 days on study at the time of the IA.  
The second IA happens 14 days after approximately 124 patients are randomized . This IA is for 
futility and sample size reestimation. An unblinded sample size re-estimation (SSR), is planned 
to be performed at this IA. The unblinded SSR will be based on the method of conditional power 
(CP). It is defined as the probability to detect a statistically significant difference for the primary 
endpoint at the end of study given the current data observed at this  IA, assuming this interim 
trend continues. The CP will be calculated for the primary endpoint at this IA using East 
software with CHW method ( Cui 1999).  
The odds ratio and associated p- value  will be obtained for the primary endpoint OSI  between 
two arms based on the observed data at this IA, then the CP will be calculated using East. The calculated CP will be assigned to one o f the 3 zones:  
1. favorable (CP ≥80%)  
2. promising (30% ≤ CP <80%)  
3. unfavorable (CP<30%)  
The original planned total sample size of approximately 247 patients will be increased to achieve 
the targeted power of 80%, up to a maximum of 371 patients when the conditional power is in the promising zone. If the CP is <30%, the trial may be stopped for futility (non-binding). Otherwise, if the CP is ≥80% the total sample size will remain at [ADDRESS_209345] ( DSMB) to determine if the trial will be stopped for 
futility , adjust the sample size,  or continue as planned. 
Clinical Study Protocol: XPORT -CoV -1001               Selinexor  
Version 6.0                                                                                                                                                08 May 2020 
Confidential   Page 61 of 74 10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS  
10.1. Ethical and Administrative Obligations  
10.1.1. Regulatory and Ethical Considerations 
This clinical study was designed and shall be implemented and reported in accordance with the 
International Conference on Harmonisation (ICH) Harmonized Tripartite Guidelines for Good 
Clinical Practice, with applicable local regulations (including European Directive 2001/20/EC 
and US Code of Federal Regulations (CFR) Title 21), and with the ethical principles that originate from the Declaration of Helsinki.  
The protocol and the proposed ICF(s) must be reviewed and approved by a properly constituted IRB/IEC before study start. Prior to study start, the Investigator is required to sign a protocol signature [CONTACT_5389]/her agreement to conduct the study in accordance with these 
documents and all of the instructions and procedures found in this protocol and to give access to 
all relevant data and records to Karyopharm monitors, auditors, designated agents of Karyopharm, IRBs/IECs, and regulatory authorities as required. 
Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate hazard to study patients.  
10.1.2. Responsib ilities of the Investigator and Good Clinical Practice  
The I nvestigator will be responsible for the following: 
• Providing written summaries of the status of the study to the IRB/IEC annually or more frequently in accordance with the requirements, policies, and procedures 
established by [CONTACT_1201]/IEC  
• Notifying the IRB/IEC of SAEs or other significant safety findings as required by 
[CONTACT_1744]/IEC procedures  
• Providing oversight of the conduct of the study at the site and adherence to requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 536/2014 for clinical studies (if applicable), and all other applicable local regulations  
10.2. Financial Disclosure  
Investigators and sub- investigators will provide the sponsor with sufficient, accurate financial 
information  as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Investigators are 
responsible for providing information on financial interests during the course of the study and for 
1 year after completion of the study. 
10.3. Informed Consent Process  
The Informed Consent Form (ICF) and the process to obtain the informed consent will comply 
with all local laws, regulations , and guidance. Karyopharm will provide to Investigators, in a 
separate document, proposed ICFs that are considered appropriate for this study and comply with 
Clinical Study Protocol: XPORT -CoV -[ADDRESS_209346] be agreed to by [CONTACT_178208]/IEC, and a copy of 
the approved version(s) must be provided to the Karyopharm after IRB/IEC approval. 
All patients, proxies or legal guardians must provide signed written or verbal informed consent 
as follows:  
• In a COVID -19 clinical trial, informed consent may be verbal in the presence of 
another hospi[INVESTIGATOR_178168]/or a patient representative. In this case informed consent will be documented in the patient’s chart and informed consent will be 
obtained per usual practice when the pat ient or patient’s representative is able to 
provide after contamination concerns are no longer an issue.  
• In a COVID -[ADDRESS_209347] dose . If there is any question that the patient will not reliably 
comply, they should not be entered in the study. 
• The investigator or his/her representative will explain the nature of the study to the patient  or his/her legally authorized representative or proxy and answer all  questions 
regarding the study. 
• Patient s must be informed that their participation is voluntary. Patient s or their legally 
authorized representative will be required to sign a statement of informed consent that meets the requirements of [ADDRESS_209348] (HIPAA) requirements, where 
applicable, and the IRB/IEC or study center. 
• The medical record must include a statement that written informed consent was 
obtained before the patient  was enrolled in the study and the date the written consent 
was obtained. The authorized person obtaining the informed consent must also sign 
the ICF.  
• Patient s must be re-consented to the most current version of the ICF(s) during th eir 
participation in the study.  
• A copy of the ICF(s) must be provided to the patient  or the patient ’s legally 
authorized representati ve. 
Males should be informed that taking the study drug may lead to reductions in sperm counts, including marked reductions. Recovery from this may take weeks or months and may not be 
complete and the effects on sperm during recovery are not known.   In order to participate in the 
study, males must adhere to the contraception requirement for the duration of the study and for [ADDRESS_209349] dose. If there is any question that the patient will not reliably comply, they 
should not be entered in the study. 
Clinical Study Protocol: XPORT -CoV -[ADDRESS_209350] be kept strictly confidential to enable patient identification at the site.  
Any patient records or datasets that are transferred to Karyopharm will contain the identifier only; patient names or any information which would make the patient identifiable will not be transferred.  
Information about study patients will be kept confidential and managed under the applicable laws and regulations. Those regulations require a signed patient authorization informing the patient of the following:  
• What protected health information (PHI) will be collected from patients in this study  
• Who will have access to that information and why.  
• Who will use or disclose that information .  
• The rights of a research patient to revoke their authorization for use of their PHI.  
In the event that a patient revokes authorization to collect or use PHI, the Investigator, by [CONTACT_5151], retains the ability to use all information collected prior to the revocation of patient 
authorization. For patients that have revoked authorization to collect or use PHI, attempts should 
be made to obtain permission to collect follow-up safety information ( e.g., has the patient 
experienced any new or worsened AEs) at the end of their scheduled study period. 
The data collection system for this study uses built- in security features to encrypt all data for 
transmission in both directions, preventing unauthorized access to confidential patient 
information. Access to the system will be controlled by a sequence of individually assigned user 
identification codes and passwords, made available only to authorized personnel who have 
completed prerequisite training. 
10.4.2. Site Monitoring  
Before site activation , Karyopharm personnel (or designated contract research organization 
[CRO] ) will review the protocol and applicable study documents with the Investigators and their 
staff (e.g., at a site initiation visit). During the study, the monitor must have access to the source 
documents to check the completeness of patient records, accuracy of entries on the CRFs, 
adherence to the protocol and to Good Clinical Practice (GCP), progress of enrollment, and to 
ensure that study treatment is being stored, dispensed, and accounted for according to specifications. Key study personnel must be available to assist the monitor during these visits. 
Remote study monitoring could be used, more details will be provided in the study- specific 
monitoring plan.  
The Investigator must maintain source documents for each patient in the study, consisting of case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical 
information, laboratory data, ECGs, and the results of any other tests or assessments. All information recor ded on CRFs must be traceable to source documents in the patient's file. The 
Investigator must also keep the original signed ICF (a signed copy is given to the patient). 
Clinical Study Protocol: XPORT -CoV -[ADDRESS_209351] give the monitor access to all relevant source documents to conf irm their 
consistency with the CRF entries. Karyopharm monitoring standards require full verification for 
the presence of informed consent, adherence to the inclusion/exclusion criteria and 
documentation of SAEs. Additional checks of the consistency of the source data with the CRFs are performed according to the study-specific monitoring plan. 
10.4.3. Data Collection  
This study will utilize electronic data capture (EDC), the designated clinical site staff will enter 
the data required by [CONTACT_178209]. The eCRFs will be constructed using fully validated secure web -enabled software that conforms to [ADDRESS_209352], which employs the Anatomical Therapeutic Chemical (ATC) classification system. Medical history/current medical conditions and AEs will be coded using the MedDRA terminology. 
10.4.4. Database Management and Quality Control 
Karyopharm personnel (or designated CRO) will review the  eCRF data entered by 
[CONTACT_5375]. Electronic data queries stating the nature of 
the problem and requesting clarification will be created for discrepancies and missing values and 
sent to the investigational site via the  electronic data capture ( EDC) system. Designated 
Investigator site staff are required to respond promptly to queries and to make any necessary changes to the data.  
At the conclusion of the study, after discrepancies and missing values have been complet ed and 
the data have been verified to be complete and accurate, the database will be declared locked.  
For EDC studies, after database lock, the Investigator will receive a CD -ROM or paper copi[INVESTIGATOR_178169].  
10.5. Data Safety Monitoring Committee  
At the interim analyses, primary efficacy outcome and /or safety outcomes will be reviewed by 
[CONTACT_178210]  
(Section  9.5). The DSMB will meet at least three times during the course of the study. 
Enrollment will be paused for evaluation of safety and efficacy after the enrollment of the first 
[ADDRESS_209353] 40 patients will be shared with the FDA prior to resuming enrollment. The remaining  DSMB meetings are planned to evaluate the data from the 
IA. The DSMB may also meet at other times during the study as needed.   
Clinical Study Protocol: XPORT -CoV -[ADDRESS_209354] 3 members who are independent of 
Karyopharm and the study .  The DSMB will meet to evalu ate safety and efficacy , to ensure the 
appropriate benefit risk profile for patients enrolled in the study and to review any SAEs that 
occur during the study. The DSMB will be provided with all reports of AEs including SAEs regardless of Investigator causality assessments.  
Details on how the DSMB will review safety and response data are provided in the DSMB Charter. The DSMB review will include, but not be limited to , evaluations of duration of therapy 
and all cause and AE -related dose reductions, interruptions , and discontinuations. At the interim 
analyses, primary efficacy outcome and selected safety outcomes will be reviewed by [CONTACT_178210].  
10.6. Dissemination of Clinical Study Data  
Results from th e study (including demographics, baseline characteristics, primary and secondary 
endpoints) will be posted in a publicly accessible database (such as www.clinicaltrials .gov or 
EudraCT) in accordance with applicable laws, regulations, and/or guidelines.  
In addition, upon study completion and finalization of the clinical study report, the results of this 
study may be submitted for publication in a peer- reviewed journal or presented at a 
scientific/biomedical conference.  
10.7. Source Documents  
Each participating si te will maintain appropriate medical and research records for this study, in 
compliance with Section 4.9 of the ICH E6 GCP, and regulatory and institutional requirements 
for the protection of confidentiality of subjects. As part of participating in a Karyopharm-sponsored study, each site will permit authorized representatives of Karyopharm and regulatory 
agencies to examine (and when required by [CONTACT_1289], to copy) clinical records for the 
purposes of quality assurance reviews, audits and evaluation of the study safety and progress. 
Source data are all information, original records of clinical findings, observations, or other 
activities in a clinical study necessary for the reconstruction and evaluation of the study. 
Examples of these original documents and data records include, but are not limited to, hospi[INVESTIGATOR_1097], clinical and office charts, laboratory notes, memoranda, patients’ diaries or evaluation 
checklists, pharmacy dispensing records, recorded data from automated instruments, copi[INVESTIGATOR_178170], microfiches, 
photographic negatives, microfilm or magnetic media, x-rays, and patient files and records kept 
at the pharmacy, at the laboratories, and medico- technical departments invol ved in the clinical 
study. 
The Investigator/institution should maintain the study documents as specified in Essential 
Documents for the Conduct of a Clinical Trial (ICH E6 Section 8) and as required by [CONTACT_5383]/or guidelines. The Investig ator/institution should take measures to prevent 
accidental or premature destruction of these documents.  
Essential documents (written and electronic) should be retained for a period of not less than fifteen (15) years from the completion of the clinical study unless Karyopharm provides written 
permission to dispose of them or, requires their retention for an additional period of time because 
of applicable laws, regulations and/or guidelines. 
Clinical Study Protocol: XPORT -CoV -[ADDRESS_209355] been collected and a study- site closure visit has been performed.  
The I nvestigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination. 
Reasons for the early closure of a study site by [CONTACT_9330]: 
• Failure of the Investigator to comply with the protocol, the requirements of the IRB/IEC or local health authorities, the Sponsor's procedures, or GCP guidelines 
• Inadequa te recruitment of patients by [CONTACT_737] 
• Discontinuation of further study treatment  development 
10.9. Publication Policy  
• The results of this study may be published or presented at scientific meetings. If this is foreseen, the investigator agrees to submit all manuscripts or abstracts to the 
sponsor before submission. This allows the sponsor to protect proprietary information 
and to provide comments. 
• The sponsor will comply with the requirements for publication of study results. In 
accordance with standard editorial and ethical practice, the sponsor will generally 
support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator [INVESTIGATOR_9231].  
• Authorship will b e determined by [CONTACT_14346].  
Clinical Study Protocol: XPORT -CoV -1001               Selinexor  
Version 6.0                                                                                                                                                08 May 2020 
Confidential   Page 67 of 74 11. REFERENCES 
Behrens, Ryan T., Mounavya Aligeti, Ginger M. Pocock, Christina A. Higgins, and Nathan M. 
Sherer. 2017. “Nuclear Export Signal Masking Regulates HIV-1 Rev Trafficking and Viral 
RNA Nuclear Export.” Journal of Virology  91 (3). https://doi.org/10.1128/jvi.[ZIP_CODE] -16. 
Cascella, Marco, Michael Rajnik, Arturo Cuomo, Scott C. Dulebohn, and Raffaela Di Napoli. 
2020. Features, Evaluation and Treatment Coronavirus (COVID-19) . StatPearls . StatPearls 
Publishing. http://www.ncbi.nlm.nih.gov/pubmed/32150360. 
Crochiere M, Hannus S, Hansen K, et al., (2017) XPO1 target occupancy measurements confirm 
the selinexor recommended phase 2 dose.” Oncotarget. 2017;8(66):110503-16. 
Cui L, Hung HM, Wang SJ. Modification of sample size in group sequential clinical trials. 
Biometrics. 1999 Sep;55(3):853 -7. 
Garzon R , Savona M, Baz R, Andreeff M, Gabrail N, Gutierrez M, et al. A phase 1 clinical trial 
of single-agent selinexor in acute myeloid leukemia. Blood 2017;129: 3165–74.  
Gavriatopoulou, Maria, Ajai Chari, Christine Chen, Nizar Bahlis, Dan T. Vogl, Andrzej 
Jakubowiak, David Dingli, et al. 2020. “Integrated Safety Profile of Selinexor in Multiple 
Myeloma: Experience from 437 Patients Enrolled in Clinical Trials.” Leukemia , February, 
1–11. https://doi.org/10.1038/s41375-020-0756-6. 
Gordon DE, Jang GM, Bouhaddou M, et al., (2020). A SARS- CoV-2-human protein-protein 
interaction map reveals drug targets and potential drug-repurposing. 2020. bioRxiv, available at:  https://doi.org/10.1101/2020.03.22.002386. 
Huang, Chaolin, Yeming Wang, Xingwang Li, Lili Ren, Jianpi[INVESTIGATOR_178171], Yi Hu, Li Zhang, et al. 
2020. “Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China.” The Lancet  395 ([ZIP_CODE]): 497–506. https://doi.org/10.1016/S0140-6736(20)[ZIP_CODE]-
5. 
Kashyap , Trinayan, Christian Argueta, Amro Aboukameel, Thaddeus John Unger, Boris 
Klebanov, Ramzi M. Mohammad, Irfana Muqbil, et al. 2016. “Selinexor, a Selective Inhibitor of Nuclear Export (SINE) Compound, Acts through NF- ΚB Deactivation and 
Combines with Proteasome Inhibitors to Synergistically Induce Tumor Cell Death.” Oncotarget 7 (48): [ZIP_CODE]–95. https://doi.org/10.[ZIP_CODE]/oncotarget.[ZIP_CODE]. 
Kuruvilla, John, Michael Savona, Rachid Baz, Paul Morten Mau- Sorensen, Nashat Gabrail, 
Ramiro Garzon, Richard Stone, et al. 2017. “Selective Inhibition of Nuclear Export with Selinexor in Patients with Non -Hodgkin Lymphoma.” Blood 129 (24): 3175–83. 
https://doi.org/10.1182/blood-2016-11-750174. 
Jorquera, Patricia A., Cynthia Mathew, Jennifer Pi[INVESTIGATOR_148016], Colin Williams, Jasmina M. Luczo, 
Sharon Tamir, Reena Ghildyal, and Ralph A. Tripp. 2018. “ Verdinexor (KPT-335), a Selective Inhibitor of Nuclear Export, Reduces Respi[INVESTIGATOR_178172] .” Journal of Virology  93 (4). https://doi.org/10.1128/jvi.[ZIP_CODE]-18. 
Lai, Chih Cheng, Tzu Pi[INVESTIGATOR_178173], Wen Chien Ko, Hung Jen Tang, and Po Ren Hsueh. 2020. 
“Severe Acute Respi[INVESTIGATOR_7531] 2 (SARS- CoV-2) and Coronavirus 
Disease- 2019 (COVID-19): The Epi[INVESTIGATOR_178174].” International Journal of 
Antimicrobial Agents . Elsevier B.V. https://doi.org/10.1016/j.ijantimicag.2020.105924. 
Landesman et al., (2012) Pharmacokinetic (PK) / Pharmacodynamic (PDn) and Efficacy 
Relationship of Selective Inhibitors of Nuclear Export (KPT -SINE) [ADDRESS_209356], Elizabeth Howerth, et al. 2016. “Antiviral Efficacy of Verdinexor in Vivo in Two Animal Models of Influenza a Virus Infection.” PLoS ONE  11 (11). 
Clinical Study Protocol: XPORT -CoV -1001               Selinexor  
Version 6.0                                                                                                                                                08 May 2020 
Confidential   Page 68 of 74 https://doi.org/10.1371/journal.pone.0167221. 
Razak , Abdul, Albiruni R, Morten Mau-Soerensen, Nashat Y Gabrail, John F Gerecitano, 
Anthony F Shields, Thaddeus J Unger, Jean R Saint-Martin, et al. 2016. “First- in-Class, 
First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in 
Patients With Advanced Solid Tumors.” Journal of Clinical Oncology : Official Journal of 
the American Society of Clinical Oncology 34 (34): 4142–50. https://doi.org/10.1200/JCO.2015.65.3949. 
Reed, M. L., G. Howell, S. M. Harrison, K.-A. Spencer, and J. A. Hiscox. 2007. 
“Characterizati on of the Nuclear Export Signal in the Coronavirus Infectious Bronchitis 
Virus Nucleocapsid Protein.” Journal of Virology 81 (8): 4298–4304. https://doi.org/10.1128/jvi.[ZIP_CODE]-06. 
Ruan, Qiurong, Kun Yang, Wenxia Wang, Lingyu Jiang, and Jianxin Song. 2020. “ Clinical 
Predictors of Mortality Due to COVID -19 Based on an Analysis of Data of 150 Patients 
from Wuhan, China.” Intensive Care Medicine. Springer. https://doi.org/10.1007/s00134-020-[ZIP_CODE]-x. 
Senapedis WT., Baloglu E., Landesman Y., (2014) Clinical translation of nuclear export 
inhibitors in cancer. Seminars in Cancer Biol. 2014 Aug;27:74-86. doi: 10.1016/j.semcancer.2014.04.005. 
Sharma, Kulbhushan, Sara Åkerström, Anuj Kumar Sharma, Vincent T. K. Chow, Shumein 
Teow, Bernard Abrenica, Stephanie A. Booth, Timothy F. Booth, Ali Mirazimi, and Sunil K. Lal. 2011. “SARS-CoV 9b Protein Diffuses into Nucleus, Undergoes Active Crm1 Mediated Nucleocytoplasmic Export and Triggers Apoptosis When Retained in the Nucleus.” Edited by [CONTACT_178211] V. Aguilar. PLoS ONE 6 (5): e19436. https://doi.org/10.1371/journal.pone.0019436. 
Sun et al., (2013) Nuclear export inhibition through covalent conjugation and hydrolysis of  
Leptomycin B by [CONTACT_178212]1. Proc Natl Acad Sci U S A. 2013 Jan 22; 110(4): 1303–1308.  DOI:10.1073/pnas.[PHONE_3845] 
Tai YT, Landesman,Y, Acharya C, et al., (2014) CRM1 inhibition induces tumor cell 
cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia. 2014; 28:155-65. 
Tajiri, Naoki, Ike De La Peña, Sandra A. Acosta, Yuji Kaneko, Sharon Tamir, Yosef 
Landesman, Robert Carlson, Sharon Shacham, and Cesar V. Borlongan. 2016. “A Nuclear Attack on Traumatic Brain Injury: Sequestration of Cell Death in the Nucleus.” CNS Neuroscience and Therapeutics 22 (4): 306–15. https://doi.org/10.1111/cns.[ZIP_CODE]. 
Tamir et al., (2016) Verdinexor, a Clinical- Stage Selective Inhibitor of Nuclear Export (SINE™) 
Compound, Demonstrates a Wide Therapeutic Window and Low Susceptibility to Resistance Development in Mouse Models of Influenza A. International Society for Influenza and other Respi[INVESTIGATOR_178175], Aug 24 –28, 2016; Chicago, IL. 
Widman, Douglas G., Savanna Gornisiewicz, Sharon Shacham, and Sharon Tamir. 2018. “In 
Vitro Toxicity and Efficacy of Verdinexor, an Exportin 1 Inhibitor, on Opportunistic Viruses Affecting Immunocompromised Individuals.” PLoS ONE  13 (10). 
https://doi.org/10.1371/journal.pone.0200043. 
Wu, Ming, Huan Gui, Zongtai Feng, Hua Xu, Gang Li, Mei Li, Ting Chen, et al. 2018. “KPT-
330, a Potent and Selective CRM1 Inhibitor, Exhibits Anti- Inflammation Effects and 
Protection against Sepsis.” Biochemical and Biophysical Research Communications  503 
(3): 1773–79. https://doi.org/10.1016/j.bbrc.2018.07.112. 
Clinical Study Protocol: XPORT -CoV -1001               Selinexor  
Version 6.0                                                                                                                                                08 May 2020 
Confidential   Page 69 of 74 Zhou, Yadi, Yuan Hou, Jiayu Shen, Yin Huang, William Martin, and Feixiong Cheng. 2020. 
Network -Based Drug Repurposing for Human Coronavirus . MedRxiv. Cold Spring Harbor 
Laboratory Press. https://doi.org/10.1101/2020.02.03.20020263. 
Cli nical St u d y Pr ot oc ol: X P O R T -C o V -[ADDRESS_209357] u d y Pr ot oc ol: X P O R T -C o V -1 0 0 1                     Seli ne x or  
Versi o n 6. 0                                                                                                                                                 0 8 Ma y 2 0 2 0  
C o nfi de ntial   Pa ge 7 1  of 7 4   C CI 
Clinical Study Protocol: XPORT -CoV -1001               Selinexor  
Version 6.0                                                                                                                                                08 May 2020 
Confidential   Page 72 of 74 APPENDIX 2. SAFETY AND TOLERABILITY OF SELINEXOR 20 -MG 
DOSE  
Please see the safety data available for the 20mg dose of selinexor ( Table 7 ) These data were 
generated in two phase 1 studies evaluating escalating doses of selinexor in patients with heavily 
pretreated, progressive, relapsed refractory hem atological malignancies and solid tumors.  
• Study KCP-330-001: A Phase 1 Study of the Pharmacokinetics and Pharmacodynamics of 
Escalating Doses of the Selective Inhibitor of Nuclear Export (SINE) KPT -330 in Patients 
with Advanced Hematological Malignancies;  [STUDY_ID_REMOVED]  
• Study KCP- 330-002: A Phase 1 Study of the Pharmacokinetics and Pharmacodynamics of Escalating Doses of the Selective Inhibitor of Nuclear Export (SINE) KPT -330 in Patients 
with Advanced or Metastatic Solid Tumor Malignancies; [STUDY_ID_REMOVED].  
A summary of the findings from these studies are as follows: Twenty -five patients received a 
dose of ≤12 mg/m
2 (~20 mg) from two Phase 1 dose escalation studies in patients with advanced 
heavily pretreated hematologic (KCP - 330-001) and solid tumors (KCP- 330- 002) and were 
included in the analysis. These patients had multiple lines of prior chemotherapy and were 
severely immunocompromised frail patients with heavily pre -treated relapsed refractory 
hematologic and solid tumors.   At a dose ≤12 mg/m
2 (≤ ~20 mg) in the first [ADDRESS_209358] common non-hematologic 
adverse events (AEs) were low grade (Grade 1 and 2) nausea, decreased appetite, fatigue, vomiting and dysgeusia, that was manageable with supportive care. Hematologic AEs included only thrombocytope nia (Table 7 ) and the Grade 3 and 4 events (1 each) were observed in 
patients with refractory hematologic cancers (acute leukemia and myeloma). Note there were no grade 5 (death) events. There were no clinically significant changes in serum chemistries.  Nearly all of the adverse events were reversible and responded to supportive care.  Finally, there were no clinically significant drug -drug interactions at these low doses, nor were any observed at 
much higher doses. As these patients have refractory cancers that have progressed on available therapi[INVESTIGATOR_014], they will generally have more medical problems than the majority of the patients entering the proposed COVID- 19 study, and therefore this represents a ‘worst case’ scenario.  
 
Conclusion.  Based on the data pre sented here, the highly selective and potent oral XPO1 
inhibitors verdinexor and selinexor have no clinically important discernable differences, 
both have activity in models of sepsis, inflammation and influenza, and the adverse event profile of low dose selinexor consists of low grade, reversible and treatable symptoms.  
  
Clinical Study Protocol: XPORT -CoV -1001               Selinexor  
Version 6.0                                                                                                                                                08 May 2020 
Confidential   Page 73 of 74 Table 7:  Adverse Event (AE) Profile of Low Dose (≤20 mg) Selinexor  from Phase 1 
Studies in Patients with Advanced Refractory Hematologic and Solid Tumor 
Malignancies.  
 
 
 

Clinical Study Protocol: XPORT -CoV -[ADDRESS_209359] John's Wort extract  
Strong  CYP3A  inhibitors   VIEKIRA pak, indinavior/RIT, tipranavir/RIT,  ritonavir, cobicistat (GS -9350), ketoconazole, indinavir, troleandomycin, 
telaprevir, dano previr / RIT, elvitegravir / RIT, saquinavir / RIT, 
lopi[INVESTIGATOR_054] / RIT, itraconazole, voriconazole, mifepristone, mibefradil, clarithromycin, posaconazole, telithromycin, grapefruit 
juice DS, ceritinib, conivaptan, nefazodone, nelfinavir, aquinavir, ribociclib, idelalisib , boceprevir  
 
Note: This is based on Metabolism and Transport Drug Interaction Database 
(https://www.druginteractioninfo.org/ ), and is not an exhaustive list.  For an updated FDA list, 
see the following link: https:/ /www.fda.gov/drugs/drug- interactions -labeling/drug-development-
and-drug- interactions -table -substrates -inhibitors -and-inducers#cypEnzymes .   
 